CLOV Clover Health Investments Corporation

---

---

---

---

---

---

---

---

---

---

Clover Health Investments, Corp. (collectively with its affiliates and subsidiaries, "Clover" or the "Company") is focused on empowering physicians to identify and manage chronic diseases early. Clover has centered its strategy on building and deploying technology through its flagship software platform, Clover Assistant, to help America's seniors receive better care at lower costs.

Clover aims to provide affordable, high-quality Medicare Advantage plans, including Preferred Provider Organization ("PPO") and Health Maintenance Organization ("HMO") plans, through its regulated insurance subsidiaries. The Company's regulated insurance subsidiaries consist of Clover Insurance Company and Clover HMO of New Jersey Inc., which operate the Company's PPO and HMO health plans, respectively. On April 1, 2021, the Company's subsidiary, Clover Health Partners, LLC ("Health Partners"), began participating as a Direct Contracting Entity ("DCE") in the Global and Professional Direct Contracting Model ("DC Model") of the Centers for Medicare and Medicaid Services ("CMS"), an agency of the United States Department of Health and Human Services, through which the Company had previously provided care to aligned Medicare fee-for-service ("FFS") beneficiaries (the "Non-Insurance Beneficiaries") through our prior participation in ACO REACH Program, as defined herein. CMS redesigned the DC Model and renamed it the Accountable Care Organization ("ACO") Realizing Equity, Access, and Community Health ("REACH") ("ACO REACH") Model effective January 1, 2023. On December 1, 2023, the Company notified CMS that it will no longer participate as a REACH ACO in the CMS ACO Reach Program, effective as of the end of the 2023 performance year. The Company’s exit from the ACO REACH Program follows its November 2022 announcement of a strategic reduction in the number of ACO REACH participating physicians in 2023, and was made after the Company determined that it is in the Company's best interest to fully exit the ACO REACH Program starting with the 2024 performance year. The activity recognized during 2024 relates to prior performance years with CMS and are presented in discontinued operations for all periods presented in the condensed consolidated financial statements. See Note 17 for further discussion of discontinued operations. Medical Service Professionals of NJ, LLC, houses Clover's employed physicians and the related support staff for Clover's in-home care program. Clover's administrative functions and insurance operations are primarily operated by its Clover Health, LLC and Clover Health Labs, LLC subsidiaries.

For any information following the aforementioned paragraph, the Company will refer to its participation in ACO REACH Model or the Company's participation in the predecessor DC Model as ACO REACH Model henceforth.

Clover's approach is to combine technology, data analytics, and preventive care to lower costs and increase the quality of health and life of Medicare beneficiaries. Clover's technology platform is designed to use machine learning-powered systems to deliver data and insights to physicians in order to improve outcomes for beneficiaries through the early identification and management of chronic disease and drive down costs. Clover's MA plans generally provide access to a wide network of primary care providers, specialists, and hospitals, enabling its members to see any doctor participating in Medicare willing to accept them. Clover focuses on minimizing members' out-of-pocket costs and offers many plans that allow members to pay the same co-pays for primary care provider visits regardless of whether their physician is in- or out-of-network.

During the second quarter of 2024, the Company launched Counterpart Health, Inc., a new Software-as-a-Service (“SaaS”) and Tech Enabled Services Solution to bring the power of CA Technology to Medicare Advantage payors and providers. This external offering aims to equip clinician users with the Company's already built, clinician-centric, and AI-powered care management platform. Strategically, Counterpart Health, Inc., a subsidiary of Clover Health, aims to extend the benefits of data-driven proven technology and personalized care to a wider audience, enabling enhanced patient outcomes and reduced healthcare costs across the nation. Counterpart Health is complementary to Clover Health, and enables the Company to deploy and expand the reach of its existing technology asset for new potential growth and high margin business opportunities, with low startup costs.

For additional information, see Note 1 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K").

---

Basis of presentation

The Company's condensed consolidated financial statements have been prepared in conformity with the generally accepted accounting principles in the United States ("GAAP") as well as in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and include the accounts of the Company and its wholly-owned subsidiaries. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, necessary for a fair presentation of its financial condition and its results of operations for the periods presented. All material intercompany balances and transactions have been eliminated in consolidating these financial statements. Investments over which we exercise significant influence, but do not control, are accounted for using the applicable accounting treatment based on the nature of the investment. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the 2023 Form 10-K.

Use of estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and the accompanying notes.

The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, reinsurance, premium deficiency reserve, stock-based compensation, recoveries from third parties for coordination of benefits, and final determination of medical cost adjustment pools.

Reclassifications

Certain amounts in the prior year's Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current year's presentation, primarily related to Surety bonds and deposits and Change in restricted cash related to surety bonds, deposits, and escrow accounts.

Discontinued Operations

The results of operations for the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Assets and liabilities related to the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented in the Condensed Consolidated Balance Sheets. Refer to Note 17 (Discontinued Operations) for additional information.

Equity method of accounting and variable interest entities

Investments in entities in which the Company does not have control but its ownership falls between 20.0% and 50.0%, or it has the ability to exercise significant influence over operating and financial policies, are accounted for under the equity method of accounting.

The Company continuously assesses its partially-owned entities to determine if these entities are variable interest entities ("VIEs") and, if so, whether the Company is the primary beneficiary and, therefore, required to consolidate the VIE. To make this determination, the Company applies a qualitative approach to determine whether the Company has both the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. If the Company has an interest in a VIE but is determined to not be the primary beneficiary, the Company accounts for the interest under the equity method of accounting.

When the Company's carrying value in an equity method investee company is reduced to zero, no further losses are recorded in the Company's condensed consolidated financial statements unless the Company guaranteed obligations of the investee company or has committed additional funding. When the investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.

---

Segment information

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. At September 30, 2024, the Company has one reportable segment, Insurance. Beginning in 2024, the Company exited the ACO REACH Model and as a direct result, the reportable operating segment formerly known as Non-Insurance no longer meets the criteria of a required reportable operating segment.

Capitalized software development costs - cloud computing arrangements

The Company's cloud computing arrangements are mostly comprised of hosting arrangements that are mostly service contracts, whereby the Company gains remote access to use enterprise software hosted by the vendor or another third party on an as-needed basis for a period of time in exchange for a subscription fee. Implementation costs for cloud computing arrangements are capitalized if certain criteria are met and consist of internal and external costs directly attributable to developing and configuring cloud computing software for its intended use. These capitalized implementation costs are presented in the Condensed Consolidated Balance Sheets within Prepaid expenses and are generally amortized over the fixed, non-cancelable term of the associated hosting arrangement on a straight-line basis.

Deferred acquisition costs

Acquisition costs directly related to the successful acquisition of new business, which are primarily made up of commissions costs, are deferred and subsequently amortized. Deferred acquisition costs are recorded within Other assets, current in the Condensed Consolidated Balance Sheets and are amortized over the estimated life of the related contracts. The amortization of deferred acquisition costs is recorded within General and administrative expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. For the three months ended September 30, 2024 and 2023, charges related to deferred acquisition costs of $2.7 million and $0.6 million, respectively. For the nine months ended September 30, 2024 and 2023, charges related to deferred acquisition costs of $5.5 million and $5.8 million, respectively, were recognized in General and administrative expenses.

Restructuring Activities

Restructuring related expenses, which are recorded within Restructuring costs in the Condensed Consolidated Statements of Operations and Comprehensive Loss, include employee termination benefits, vendor costs associated with restructuring activities, and other costs associated with the business transformation initiatives. Restructuring costs are determined based on estimates, which are prepared at the time the restructuring actions are approved by management and are periodically reviewed and updated for changes in estimates. The Company applies the provisions of ASC 420, Exit or Disposal Cost Obligations ("ASC 420") as these costs meet the criteria of a one-time benefit. Under ASC 420-10, the Company establishes a liability for a cost associated with an exit or disposal activity, including employee termination benefits and other restructuring related costs, when the liability is incurred, rather than at the date that the Company commits to an exit plan. At each reporting date, there is an evaluation of the liability to ensure the amount is still appropriate. See Note 16 (Restructuring costs) for further discussion.

Recent accounting pronouncements

Recently adopted accounting pronouncements

There have been no new accounting pronouncements adopted during the nine months ended September 30, 2024 that had a material impact on the Company's condensed consolidated financial statements.

Accounting pronouncements effective in future periods

In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement—Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation—Stock Compensation (Topic 718); Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280—General Revision of Regulation S-X: Income or Loss Applicable to Common Stock (“ASU 2023-03”). This ASU amends or supersedes various SEC paragraphs within the applicable codification to conform to past SEC staff announcements. This ASU does not provide any new guidance. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on its condensed consolidated financial statements and related disclosures.

---

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update aim to improve reportable segment disclosures by requiring enhanced disclosures around significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual disclosures about segment profit or loss must be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years beginning after December 15, 2024. A public entity should apply ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its condensed consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update aim to provide more transparency regarding tax disclosures mainly related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its condensed consolidated financial statements and related disclosures.

The following tables present amortized cost and fair values of investments at September 30, 2024 and December 31, 2023, respectively:

September 30, 2024						Amortized cost						Accumulated unrealized gains						Accumulated unrealized losses						Fair value
						(in thousands)
Investment securities, held-to-maturity
U.S. government and government agencies and authorities						$	14,309					$	7					$	(123)					$	14,193
Investment securities, available-for-sale
U.S. government and government agencies and authorities						141,551						1,396						(1,258)						141,689
Corporate debt securities						83,321						714						(32)						84,003
Other						1,663						32						—						1,695
Total held-to-maturity and available-for-sale investment securities						$	240,844					$	2,149					$	(1,413)					$	241,580

December 31, 2023						Amortized cost						Accumulated unrealized gains						Accumulated unrealized losses						Fair value
						(in thousands)
Investment securities, held-to-maturity
U.S. government and government agencies and authorities						$	7,695					$	—					$	(225)					$	7,470
Investment securities, available-for-sale
U.S. government and government agencies and authorities						126,071						713						(3,070)						123,714
Corporate debt securities						95,354						165						(176)						95,343
Other						1,855						—						(2)						1,853
Total held-to-maturity and available-for-sale investment securities						$	230,975					$	878					$	(3,473)					$	228,380

---

The following table presents the amortized cost and fair value of debt securities at September 30, 2024, by contractual maturity:

September 30, 2024						Held-to-maturity												Available-for-sale
						Amortized cost						Fair value						Amortized cost						Fair value
						(in thousands)
Due within one year						$	15					$	15					$	43,695					$	43,302
Due after one year through five years						14,183						14,083						182,840						184,085
Due after five years through ten years						—						—						—						—
Due after ten years						111						95						—						—
Total						$	14,309					$	14,193					$	226,535					$	227,387

For the three and nine months ended September 30, 2024 and 2023, respectively, net investment income, which is included in Other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, was derived from the following sources:

						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
						(in thousands)
Cash and cash equivalents						$	4,488					$	1,944					$	10,120					$	5,978
Short-term investments						232						605						548						1,920
Investment securities						2,099						1,840						6,351						5,322
Investment income, net						$	6,819					$	4,389					$	17,019					$	13,220

Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at September 30, 2024, and December 31, 2023, respectively:

September 30, 2024						Less than 12 months												Greater than 12 months												Total
						Fair value						Unrealized loss						Fair value						Unrealized loss						Fair value						Unrealized loss
						(in thousands, except number of positions)
U.S. government and government agencies and authorities						$	10,269					$	(40)					$	39,379					$	(1,341)					$	49,648					$	(1,381)
Corporate debt securities						19,118						(30)						4,290						(2)						23,408						(32)
Total						$	29,387					$	(70)					$	43,669					$	(1,343)					$	73,056					$	(1,413)
Number of positions						21												19												40

December 31, 2023						Less than 12 months												Greater than 12 months												Total
						Fair value						Unrealized loss						Fair value						Unrealized loss						Fair value						Unrealized loss
						(in thousands, except number of positions)
U.S. government and government agencies and authorities						$	12,584					$	(32)					$	61,628					$	(3,259)					$	74,212					$	(3,291)
Corporate debt securities						61,007						(175)						5,017						(7)						66,024						(182)
Total						$	73,591					$	(207)					$	66,645					$	(3,266)					$	140,236					$	(3,473)
Number of positions						69												27												96

---

The Company did not record any credit allowances for debt securities that were in an unrealized loss position at September 30, 2024 and December 31, 2023.

At September 30, 2024, all securities were investment grade, with credit ratings of BBB+ or higher by S&P Global or as determined by other credit rating agencies within the Company's investment policy. Unrealized losses on investment grade securities are principally related to changes in interest rates or changes in issuer or sector related credit spreads since the securities were acquired. The gross unrealized investment losses at September 30, 2024, were assessed, based on, among other things:

•The relative magnitude to which fair values of these securities have been below their amortized cost was not indicative of an impairment loss;

•The absence of compelling evidence that would cause the Company to call into question the financial condition or near-term prospects of the issuer of the applicable security; and

•The Company's ability and intent to hold the applicable security for a period of time sufficient to allow for any anticipated recovery.

Proceeds from sales and maturities of investment securities, inclusive of short-term investments, and related gross realized gains (losses) which are included in Other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, were as follows for the three and nine months ended September 30, 2024 and 2023, respectively:

						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
						(in thousands)
Proceeds from sales of investment securities						$	47,804					$	—					$	47,804					$	60,436
Proceeds from maturities of investment securities						42,137						32,240						108,788						139,122
Gross realized gains						170						—						174						39
Gross realized losses						—						—						—						(19)
Net realized gains						$	170					$	—					$	174					$	20

At September 30, 2024 and December 31, 2023, the Company had $14.9 million and $14.7 million, respectively, in deposits with various states and regulatory bodies that are included as part of the Company's investment balances.

---

The following tables present a summary of fair value measurements for financial instruments at September 30, 2024 and December 31, 2023, respectively:

September 30, 2024						Level 1						Level 2						Level 3						Total fair value
						(in thousands)
U.S. government and government agencies						$	—					$	141,689					$	—					$	141,689
Corporate debt securities						—						84,003						—						84,003
Other						—						1,695						—						1,695
Warrants receivable						—						—						797						797
Total assets at fair value						$	—					$	227,387					$	797					$	228,184

December 31, 2023						Level 1						Level 2						Level 3						Total fair value
						(in thousands)
U.S. government and government agencies						$	—					$	123,714					$	—					$	123,714
Corporate debt securities						—						95,343						—						95,343
Other						1,853						—						—						1,853
Warrants receivable						—						—						814						814
Total assets at fair value						$	1,853					$	219,057					$	814					$	221,724

The changes in balances of Clover's Level 3 financial assets and liabilities during the nine months ended September 30, 2024 were as follows:

																								Warrants receivable						Total
																								(in thousands)
Balance, December 31, 2023																								$	814					$	814
Total unrealized losses																								17						17
Balance, September 30, 2024																								$	797					$	797

There were no transfers in or out of Level 3 financial assets or liabilities for the nine months ended September 30, 2024 or September 30, 2023.

Private Warrants

At September 30, 2024, the Company had exercisable private warrants which were embedded in several agreements as derivatives. These private warrants were accounted for as assets in accordance with ASC 815-40 and are presented in Other assets, non-current in the Condensed Consolidated Balance Sheets. The warrant assets are measured at fair value at inception and on a recurring basis until redeemed, with changes in fair value presented in Change in fair value of warrants in the Condensed Consolidated Statements of Operations and Comprehensive Loss. These private warrants were classified within Level 3 due to the subjectivity and use of estimates in the calculation of their fair value. These warrants at measurement date, December 31, 2023, were assessed to have a fair value of $0.8 million, with no other activity for the three months ended September 30, 2024. The Company reassesses the fair values of the warrants based on updated estimates and for the nine months ended September 30, 2024, there was less than $0.1 million unrealized losses recognized.

Healthcare receivables include pharmaceutical rebates that are accrued as they are earned and estimated based on contracted rebate rates, eligible amounts submitted to the manufacturers by the Company's pharmacy manager, pharmacy utilization volume, and historical collection patterns. Also included in Healthcare receivables are Medicare Part D settlement receivables, member premium receivables, and other CMS receivables. The Company reported $37.3 million and $64.2 million within Healthcare receivables at September 30, 2024, and December 31, 2023, respectively.

---

Related party agreements

The Company has various contracts with IJKG Opco LLC (d/b/a CarePoint Health - Bayonne Medical Center), Hudson Hospital Opco, LLC (d/b/a CarePoint Health - Christ Hospital) and Hoboken University Medical Center Opco LLC (d/b/a CarePoint Health - Hoboken University Medical Center), which collectively do business as the CarePoint Health System ("CarePoint Health"), for the provision of inpatient and hospital-based outpatient services. CarePoint Health was ultimately held and controlled by Vivek Garipalli, the Company's Executive Chairman and a significant stockholder of the Company. In May 2022, Mr. Garipalli and his family completed a donation of their interest in CarePoint Health to a non-profit organization called CarePoint Health Systems, Inc ("the CarePoint Nonprofit"). In September 2024, Sequoia Healthcare Services, LLC, an entity that Mr. Garipalli has an indirect interest in, transferred certain subsidiaries that provided services to CarePoint Health to the CarePoint Nonprofit. Following such transfer, neither Mr. Garipalli nor any entity he has an interest in currently provide any management services to CarePoint Health. However, Mr. Garipalli and certain affiliates of Mr. Garipalli are owed certain money from CarePoint Health for prior obligations. Expenses and fees incurred related to Clover's contracts with CarePoint Health, recorded in Net medical claims incurred, in the Condensed Consolidated Statements of Operations and Comprehensive Loss, were $2.5 million and $3.2 million for the three months ended September 30, 2024 and 2023, respectively, and $5.3 million and $9.7 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, $1.3 million and $1.4 million were payable to CarePoint Health at September 30, 2024, and December 31, 2023, respectively.

The Company has a contract with Medical Records Exchange, LLC (formerly known as "ChartFast," now d/b/a Credo) pursuant to which the Company receives administrative services related to medical records retrieval via Credo's electronic applications and web portal platform. Expenses and fees incurred related to this agreement were $0.1 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively, and $0.5 million and $0.6 million for the nine months ended September 30, 2024 and 2023, respectively. Vivek Garipalli, the Company's Executive Chairman and significant stockholder of the Company, is an indirect owner of Medical Records Exchange, LLC.

Since July 2, 2021, the Company has contracted with Thyme Care, Inc. ("Thyme Care"), an oncology care management company, through which Thyme Care was engaged to provide cancer care management services to the Company's Insurance members and develop a provider network to help ensure member access to high-value oncology care. The Company and Thyme Care have amended the terms of the engagement, effective April 1, 2023, to include additional clinical services available to Clover members as well as the value based payment terms. The Company entered into an agreement with Thyme Care effective September 23, 2020 where the Company purchased 1,773,049 shares (less than five percent (5%) of its class A common stock). The fair value of these shares is $1.8 million at September 30, 2024, and is recognized in Other assets, non-current, in the Condensed Consolidated Balance Sheets. In accordance with ASC 321, any changes in fair value associated with these shares are recognized in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Mr. Garipalli is a member of the board of directors of Thyme Care and holds an equity interest of less than five percent (5%) of that entity. Expenses and fees incurred related to this agreement were $0.9 million and $0.9 million for the three months ended September 30, 2024 and 2023, respectively, and $3.2 million and $1.7 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, $3.0 million and $0.2 million were payable to Thyme Care at September 30, 2024, and December 31, 2023, respectively.

---

Activity within the liability for Unpaid claims, including claims adjustment expenses, for the nine months ended September 30, 2024 and 2023, respectively, is summarized as follows:

Nine Months Ended September 30,						2024						2023
						(in thousands)
Gross and net balance, beginning of period (1)						$	137,100					$	137,395
Incurred related to:
Current year						780,461						750,705
Prior years						(31,523)						(7,689)
Total incurred						748,938						743,016
Paid related to:
Current year						622,126						646,322
Prior years						96,502						120,859
Total paid						718,628						767,181
Gross and net balance, end of period (1)						$	167,410					$	113,230

(1)    Includes amounts due to related parties.

The Company uses a variety of standard actuarial techniques to establish unpaid claims reserves. Management estimates are supported by the Company's actuarial analysis. The Company utilizes an internal actuarial team to review the adequacy of unpaid claim and unpaid claim adjustment expense. The estimation of claim costs is inherently difficult and requires significant judgment. The estimation has considerable inherent variability and can fluctuate significantly depending upon several factors, including medical cost trends and claim payment patterns, general economic conditions, and regulatory changes. The time value of money is not taken into account for the purposes of calculating the liability for unpaid claims. Management believes that the current reserves are adequate based on currently available information.

Unpaid Claims for Insurance Operations

Unpaid claims for Insurance operations were $167.4 million at September 30, 2024. During the nine months ended September 30, 2024, $96.5 million was paid for incurred claims attributable to insured events of prior years. A favorable development of $31.5 million was recognized during the nine months ended September 30, 2024, resulting from the Company's actual experience with claims developing differently as compared to the Company's estimates at December 31, 2023. A favorable development of $7.7 million was recognized during the nine months ended September 30, 2023, resulting from the Company's actual experience with claims developing differently as compared to the Company's estimates at December 31, 2022. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. The ratio of current year medical claims paid as a percentage of current year Net medical claims incurred was 79.7% for the nine months ended September 30, 2024, and 86.1% for the nine months ended September 30, 2023. This ratio serves as an indicator of claims processing speed, indicating that claims were processed at a slower rate during the nine months ended September 30, 2024, than during the nine months ended September 30, 2023. As a result of slower claims processing, unpaid claims liability increased which was primarily due to claim submission and payment process disruptions related to a third-party cyber incident.

---

Stockholders' Equity

The Company was authorized to issue up to 2,500,000,000 shares of Class A common stock at September 30, 2024 and December 31, 2023, respectively, and up to 500,000,000 shares of Class B common stock at September 30, 2024 and December 31, 2023. At September 30, 2024 and December 31, 2023, there were 411,256,965 and 401,183,882 shares of Class A common stock issued and outstanding, respectively. There were 89,032,305 and 87,867,732 shares of Class B common stock issued and outstanding at September 30, 2024 and December 31, 2023, respectively. Class B common stock has 10 votes per share, and Class A common stock has one vote per share. The Company had 16,817,010 and 7,912,750 shares held in treasury at September 30, 2024 and December 31, 2023, respectively. These amounts represent shares withheld to cover taxes upon vesting of employee stock-based awards.

On May 6, 2024, the Board of Directors of the Company authorized the repurchase of up to $20,000,000 in shares of the Company’s outstanding Class A Common Stock over a two year period. The timing, manner, price and amount of any repurchases are determined by the discretion of management, depending on market conditions and other factors. Repurchases may be made through open market purchases, including through Rule 10b5-1 trading plans, block trades or privately negotiated purchases or otherwise. The exact number of shares to be repurchased by the Company, if any, is not guaranteed, and there is no minimum number of shares that the Company is required to purchase. Depending on market conditions and other factors, these repurchases may be commenced, suspended or discontinued at any time or periodically without prior notice.

Shares repurchased by the Company are accounted for on the settlement date. Upon settlement, repurchased shares are held as treasury shares and are no longer considered outstanding. The total cost to repurchase shares includes any direct costs incurred, including broker commissions and excise taxes, and is recorded as a reduction to additional paid in capital in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2024, the Company repurchased 1,838,309 shares for an aggregate total of $1.8 million.

At September 30, 2024, the Company was authorized to issue 25,000,000 shares of preferred stock having a par value of $0.0001 per share, and the Company's Board has the authority to determine the rights, preferences, privileges, and restrictions, including voting rights, of those shares. At September 30, 2024, there were no shares of preferred stock issued and outstanding.

On February 4, 2022, Character Biosciences, Inc. (f/k/a Clover Therapeutics Company) ("Character Biosciences"), an affiliate of the Company, completed a private capital transaction in which it raised $17.9 million from the issuance of 16,210,602 shares of its preferred stock. Upon completion of the transaction, the Company owned approximately 25.46% of Character Biosciences. As a result, the Company reassessed its interest in Character Biosciences and determined that while Character Biosciences is a VIE, the Company is not considered the primary beneficiary of the VIE because it does not have the power, through voting or similar rights and the license agreements, to direct the activities of Character Biosciences that most significantly impact Character Biosciences' economic performance. On January 23, 2023, Character Biosciences, completed a second private capital transaction in which it raised additional capital from the issuance of additional shares of its preferred stock. Upon completion of this transaction, the Company's ownership percentage in Character Biosciences decreased to 23.92%.

The Company determined that it does have a significant influence over Character Biosciences and, therefore, it began accounting for its common stock investment in Character Biosciences using the equity method on February 4, 2022. As the Company applies the equity method to account for its common stock interest in Character Biosciences, the initial value of the investment is adjusted periodically to recognize (i) the proportionate share of the investee's net income or losses after the date of investment, (ii) additional contributions made and dividends or distributions received, and (iii) impairment losses resulting from adjustments to net realizable value. The Company eliminates all intercompany transactions in accounting for equity method investments and records the proportionate share of the investee's net income or loss in equity in loss on investment in the Consolidated Statements of Operations and Comprehensive Loss.

In accordance with ASC 323, Investments - Equity Method and Joint Ventures (“ASC 323”), the Company recognized the proportionate share of Character Bioscience's net loss up to the investment carrying amount. As a result, the Company did not recognize any shared gain or loss for the three months ended September 30, 2024 and 2023, respectively, and recognized a loss of $0.5 million and none for the nine months ended September 30, 2024 and 2023, respectively. The equity method investment in Character Biosciences was reduced to zero during the three months ended March 31, 2024 and no further losses can recorded in the Company's condensed consolidated financial statements as the Company did not guarantee obligations of the investee company nor has not committed additional funding. The Company will begin recognizing its share of net income only when it is greater than the cumulative net losses not recognized during the period the equity method was suspended.

---

Employee Savings Plan

The Company has a defined contribution retirement savings plan (the "401(k) Plan") covering eligible employees, which includes safe harbor matching contributions based on the amount of employees' contributions to the 401(k) Plan. The Company contributes to the 401(k) Plan annually 100.0% of the first 4.0% compensation that is contributed by the employee up to 4.0% of eligible annual compensation after one year of service. The Company's service contributions to the 401(k) Plan amounted to approximately $0.5 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively, and $1.6 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively, and are included in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company's cash match is invested pursuant to the participant's contribution direction. Employer contributions are immediately 100.0% vested.

Stock-based Compensation

The Company's 2020 Equity Incentive Plan (the "2020 Plan") provides for grants of restricted stocks units ("RSUs"), performance-based restricted stock units ("PRSUs") and stock options to acquire shares of the Company's common stock, to employees, directors, officers, and non-employee consultants of the Company and its affiliates, and the Company's 2020 Management Incentive Plan (the "2020 MIP") provides for grants of RSUs and PRSUs to the Company's Executive Chair and CEO. During the year ended December 31, 2021, the Company approved the 2020 Plan and the 2020 MIP, and the Company's 2014 Equity Incentive Plan (the "2014 Plan") was terminated. When the 2014 Plan was terminated, the outstanding awards previously granted thereunder were assumed by the Company, and no new awards are available for grant under the 2014 Plan. Shares that are expired, terminated, surrendered, or canceled under the 2014 Plan without having been fully exercised are available for awards under the 2020 Plan. On March 9, 2022, the Board adopted the Company's 2022 Inducement Award Plan (the "Inducement Plan" and, collectively with the 2020 Plan, the 2020 MIP, and the 2014 Plan, the "Plans") without stockholder approval in accordance with Nasdaq Listing Rules. Under the Inducement Plan, the Company may grant non-qualified stock options, RSUs, stock appreciation rights, and other stock or cash-based awards to an employee in connection with his or her commencement of employment, or following a bona fide period of non-employment, with the Company or an affiliate.

The 2020 Plan has an evergreen provision that requires the number of shares available for issuance under the plan to be increased on the first day of each fiscal year beginning with the 2022 fiscal year and ending on (and including) the last day of the 2024 fiscal year, in each case, in an amount equal to the lesser of (i) seven percent (7%) of the outstanding shares of Class A common Stock on the last day of the immediately preceding fiscal year and (ii) such number of shares of Class A common Stock determined by the Board; provided that for each fiscal year beginning with the 2025 fiscal year through the fiscal year that includes the expiration date of the plan, each such increase shall be reduced to the lesser of five percent (5%) of the outstanding shares of Class A common Stock on the last day of the immediately preceding fiscal year or such number of shares as determined by the Board.

The maximum number of shares of the Company's common stock reserved for issuance over the term of the Plans, shares outstanding under the Plans, and shares remaining under the Plans at September 30, 2024 were as follows:

September 30, 2024						Shares Authorized Under Plans						Shares Outstanding Under Plans						Shares Remaining Under Plans
2014 Plan						54,402,264						34,457,710						N/A
2020 Plan						86,604,581						39,844,072						19,817,658
2020 MIP						33,426,983						23,398,889						—
Inducement Plan						11,000,000						6,293,605						—

The Plans are administered by the Talent and Compensation Committee of the Board (the "Compensation Committee"). Stock options granted under the Plans are subject to the terms and conditions described in the applicable Plan and the applicable stock option grant agreement. The exercise prices, vesting, and other restrictions applicable to the stock options are determined at the discretion of the Compensation Committee, except that the exercise price per share of incentive stock options may not be less than 100.0% of the fair market value of a share of common stock on the date of grant. Stock options awarded under the Plans expire 10 years after the grant date and generally vest over four or five years. The number of stock options granted is determined by dividing the approved grant date dollar value of an option by the Black Scholes option pricing value per share (as further discussed below). RSU awards are subject to the terms and conditions set forth in the Plans and the applicable RSU grant agreement. Vesting and other restrictions applicable to RSU awards are determined at the discretion of the Compensation Committee, but generally vest over one to four years from the date of the grant. The number of RSUs granted is determined by dividing the cash value of an RSU award by the average closing price of a share of the Company's Class A common stock over a specified period through the date of grant. The total estimated grant date fair value is amortized over the requisite service period.

---

The Company recorded Stock-based compensation for stock options, RSUs, and PRSUs granted under the Plans, and discounts offered in connection with the Company's 2020 Employee Stock Purchase Plan ("ESPP") of $28.0 million and $33.1 million during the three months ended September 30, 2024 and 2023, respectively, and $84.7 million and $107.8 million during the nine months ended September 30, 2024 and 2023, respectively, and such expenses are presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Compensation cost presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss were as follows:

Three Months Ended September 30,						2024						2023
						(in thousands)
Stock options						$	384					$	559
RSUs						21,074						20,603
PRSUs						6,170						11,851
ESPP						360						57
Total compensation cost recognized for stock-based compensation plans						$	27,988					$	33,070

Nine Months Ended September 30,						2024						2023
						(in thousands)
Stock options						$	1,532					$	2,648
RSUs						62,391						62,539
PRSUs						20,327						42,444
ESPP						436						164
Total compensation cost recognized for stock-based compensation plans						$	84,686					$	107,795

At September 30, 2024, there was approximately $383.4 million of unrecognized stock-based compensation expense related to unvested stock options, unvested RSUs and unvested PRSUs, estimated to be recognized over a period of four years.

Stock Options

The Company did not grant stock options during the nine months ended September 30, 2024 and 2023, respectively.

A summary of option activity under the 2020 Plan during the nine months ended September 30, 2024, was as follows:

			Number of stock options						Weighted-average exercise price
Outstanding, January 1, 2024			952,900						$	8.88
Granted			—						—
Exercised			—						—
Forfeited			(131,212)						8.88
Outstanding, September 30, 2024			821,688						$	8.88

A summary of stock option activity under the 2014 Plan during the nine months ended September 30, 2024, was as follows:

			Number of stock options						Weighted-average exercise price
Outstanding, January 1, 2024			24,041,753						$	1.45
Granted			—						—
Exercised			(210,555)						1.16
Forfeited			(120,650)						3.44
Outstanding, September 30, 2024			23,710,548						$	2.73

---

At September 30, 2024, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $16.2 million, and a weighted-average remaining contractual term of four years. At September 30, 2024, there were 24,160,751 options exercisable under the Plan, with an aggregate intrinsic value of less than $16.2 million, a weighted-average exercise price of $2.88 per share, and a weighted-average remaining contractual term of 4.68 years. The total value of stock options exercised during the nine months ended September 30, 2024 and 2023 was $0.3 million. Cash received from stock option exercises during the nine months ended September 30, 2024 and 2023 totaled $0.2 million and none, respectively.

Restricted Stock Units

A summary of total RSU activity is presented below:

						Number of RSUs						Weighted-average grant date fair value per share
Outstanding, January 1, 2024						56,928,405						$	4.28
Granted						17,639,741						0.97
Released						(17,249,172)						4.56
Forfeited						(7,625,408)						1.93
Outstanding, September 30, 2024						49,693,566						$	3.37

Performance Restricted Stock Units

The Company has granted PRSUs to certain executives and key employees, which become eligible to vest based on achievement of certain Company or individual performance milestones (“Non-Market PRSUs”) and certain Company stock price targets (“Market PRSUs”), each as determined by the Compensation Committee. Market PRSUs will vest if prior to the vesting date the average closing price of one share of the Company's common stock for 90 consecutive days equals or exceeds a specified price. The expense referenced above is mainly attributable to Market PRSUs that vest based on pre-established milestones that primarily consist of the volume-weighted average stock closing price ranging from $20 to $30 for 90 consecutive days. The grant date fair value of the Non-Market PRSUs was based on the closing price of the Company’s Class A common stock and recognized as expense over the requisite performance period under the accelerated attribution method and is adjusted in future periods for the success or failure to achieve the specified performance condition. The grant date fair value of the Market PRSUs was determined using a Monte Carlo simulation model that incorporated multiple valuation assumptions, including the probability of achieving the specified market condition. Expense for Market PRSUs is recognized over the derived service period under the accelerated attribution method and is not adjusted in future periods for the success or failure to achieve the specified market condition.

The assumptions that the Company used in the Monte Carlo model to determine the grant date fair value of Market PRSUs granted for the year ended December 31, 2021, were as follows:

Year ended December 31, 2021
Expected volatility (1)						40.7		%
Risk-free interest rate (2)						0.5
Dividend yield (3)						—

(1) Expected volatility is based on a blend of peer group company historical data adjusted for the Company's leverage.

(2) Risk-free interest rate based on U.S. Treasury yields with a term equal to the remaining Performance Period as of the grant date.

(3) Dividend yield was assumed to be zero as the Company does not anticipate paying dividends.

At September 30, 2024, the market condition component of these PRSUs has not been met, so the awards have not been earned. This expense represents most of the PRSU expense recognized for the three and nine months ended September 30, 2024 related to stock-based compensation plans which is presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has also determined the requisite service period for the PRSUs with multiple performance conditions to be the longest of the explicit, implicit, or derived service period for each tranche.

---

A summary of PRSU activity is presented below:

						Number of PRSUs						Weighted-average grant date fair value per share
Non-vested, January 1, 2024						32,131,532						$	8.36
Granted during 2024						—						—
Adjustment for performance condition achieved(1)						341,459						0.95
Vested						(2,389,515)						1.14
Forfeited						(315,292)						1.56
Non-vested at September 30, 2024						29,768,184						$	8.93

(1) Represents an increase in the number of original CLOV performance share units awarded based on final achievement at the end of the performance period of such awards.

At September 30, 2024, there was $18.2 million of unrecognized share-based compensation expense related to PRSUs, which is expected to be recognized over a period of four years.

2020 Employee Stock Purchase Plan

On January 6, 2021, the Board adopted and the Company's stockholders approved the ESPP, which permits eligible employees and service providers of either the Company or designated related companies and affiliates to contribute up to 15% of their eligible compensation during defined offering periods to purchase shares of the Company’s Class A common stock at a 15% discount from the fair market value of the common stock as determined on specific dates at specific intervals. Subject to adjustments provided in the ESPP that are discussed below, the maximum number of shares of common stock that may be purchased under the ESPP is 14,163,863 shares, and the maximum number of shares that may be purchased on any single purchase date by any one participant is 5,000 shares. At September 30, 2024, 12,851,030 shares of Class A common stock were available for issuance under the ESPP.

The ESPP includes an evergreen provision that limits the maximum number of shares of Class A common stock that may be issued under the plan, to 2,785,582 shares, plus the number of shares of Class A common stock that are automatically added on the first day of each fiscal year beginning with the 2022 fiscal year and ending on (and including) the first day of the 2030 fiscal year, in an amount equal to the lesser of (i) one percent (1%) of the total number of shares of Class A common stock outstanding on the last day of the calendar month prior to the date of such automatic increase, and (ii) such number of shares of Class A common stock as determined by the Board; provided that the maximum number of shares of Class A common stock reserved under the ESPP shall not exceed 10.0% of the total outstanding capital stock of the Company (inclusive of the shares reserved under the ESPP) as of January 7, 2021, on an as-converted basis.

The assumptions that the Company used in the Black-Scholes option-pricing model to determine the fair value of the purchase rights under the ESPP for the most recent offering period, is as follows:

Offering period from May 22, 2024 to November 21, 2024
Weighted-average risk-free interest rate						5.4		%
Expected term (in years)						0.50
Expected volatility						64.0		%

The consolidated effective tax rate of the Company for the three and nine months ended September 30, 2024 and 2023, was 0.0%, and 0.0% respectively. The Company continues to be in a net operating loss for the nine months ended September 30, 2024 and net deferred tax asset position. As a result, and in accordance with accounting standards, the Company recorded a valuation allowance to reduce the value of the net deferred tax assets to zero. The Company believes that at September 30, 2024, it had no material uncertain tax positions. Interest and penalties related to unrecognized tax expense (benefits) are recognized in income tax expense, when applicable.

There were no material liabilities for interest and penalties accrued at September 30, 2024 and December 31, 2023.

---

Basic and diluted net loss per share from continuing operations attributable to Class A common stockholders and Class B common stockholders (collectively, "Common Stockholders") for the years indicated were calculated as follows:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
			(in thousands, except for per share and share amounts)
Numerator:
Net loss from continuing operations attributable to Common Stockholders			$	(8,785)					$	(33,616)					$	(24,785)					$	(142,203)
Net (loss) income from discontinued operations attributable to Common Stockholders			(370)						(7,853)						3,868						(686)
Denominator:
Basic weighted average number of common shares and common share equivalents outstanding			490,180,103						480,770,283						488,501,812						480,921,520
Dilutive shares:
RSU			N/A						N/A						N/A						N/A
PRSU			N/A						N/A						N/A						N/A
Stock Options			N/A						N/A						N/A						N/A
Weighted average shares used in computing net income per share of common stock, diluted			490,180,103						480,770,283						488,501,812						480,921,520
Basic loss per share from continuing operations			$	(0.02)					$	(0.07)					$	(0.05)					$	(0.30)
Basic earnings (loss) per share from discontinued operations			0.00						(0.02)						0.01						0.00
Diluted loss per share from continuing operations			(0.02)						(0.07)						(0.05)						(0.30)
Diluted earnings (loss) per share from discontinued operations			0.00						(0.02)						0.01						0.00

For all periods presented, the Company had net loss from continuing operations attributable to Common Stockholders. As a result, the Company's potentially dilutive securities, which include Options, RSUs, and PRSUs, have been excluded from the computation of diluted net loss per share from continuing operations, as the effect would be anti-dilutive. Therefore, during these periods, the diluted common shares outstanding equals the average common shares outstanding.

The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income (loss) per share of common stock:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Options to purchase common stock			24,532,236						25,138,347						24,532,236						25,138,347
RSUs			49,693,566						55,544,997						49,693,566						55,544,997
PRSUs			29,768,184						30,224,866						29,768,184						30,224,866
Total potentially dilutive shares excluded from computation of net income (loss) per share			103,993,986						110,908,210						103,993,986						110,908,210

Legal Actions

Various lawsuits against the Company may arise in the ordinary course of the Company's business. Contingent liabilities arising from ordinary course litigation, income taxes and other matters are not expected to be material in relation to the financial position of the Company. At September 30, 2024, and December 31, 2023, respectively, there were no material known contingent liabilities arising outside the normal course of business other than as set forth below. In accordance with ASC No. 450-20, Loss Contingencies, we will record accruals for loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.

---

Securities Class Actions, Derivative Litigation and Investigations

Since February 2021, the Company has received subpoenas from the SEC related to certain disclosures and aspects of our business as well as certain matters described in an article issued on February 4, 2021, by Hindenburg Research LLC (the "Hindenburg Article"). The Company is cooperating with the SEC's investigation (the "Investigation"). The Hindenburg Article, which discussed, among other things, an inquiry by the U.S. Attorney's Office for the Eastern District of Pennsylvania relating to, among other things, certain of the Company’s arrangements with providers participating in its network and programs, and Clover Assistant, was the subject of the Company’s Current Report on Form 8-K dated February 5, 2021. As previously disclosed on the Company's Current Report on Form 8-K filed on September 30, 2024, by letter dated September 26, 2024 (the “Notice”), the Staff of the SEC Division of Enforcement notified the Company that the SEC had concluded the Investigation, and based on the information that the SEC had as of the date of the Notice, the Staff did not intend to recommend an enforcement action by the SEC against the Company relating to the Investigation.

In February 2021, the Company and certain of its directors and officers were named as defendants in putative class actions filed in the United States District Court for the Middle District of Tennessee: Bond v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00096 (M.D. Tenn.); Kaul v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00101 (M.D. Tenn.); Yaniv v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00109 (M.D. Tenn.); and Tremblay v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00138 (M.D. Tenn.). The complaints assert violations of sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act. The Kaul action asserts additional claims under sections 11 and 15 of the Securities Act. The complaints generally relate to allegations published in the Hindenburg Article. The complaints seek unspecified damages on behalf of all persons and entities who purchased or acquired Clover securities during the class period (which begins on October 6, 2020, and, depending on the complaint, ends on February 3, 2021, or February 4, 2021), as well as certain other costs. In April 2021, the Middle District of Tennessee class actions were consolidated under Bond v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00096 (M.D. Tenn.) as the lead case. On June 28, 2021, the plaintiffs filed an amended complaint, which also generally relates to allegations published in the Hindenburg Article, but adds, among other things, allegations from confidential witnesses who purport to be former employees of the Company. The Company moved to dismiss the amended complaint on August 28, 2021; that motion was denied on February 28, 2022. On February 14, 2023, the court granted the plaintiffs' motion for class certification.

On April 21, 2023, the parties to the securities class action entered into a memorandum of understanding providing for the settlement of the action. The Court approved the settlement and dismissed the action with prejudice on October 3, 2023. Under the settlement, the class will receive $22 million dollars (less an award of fees and expenses to the plaintiffs’ counsel), and the defendants (including the Company) received customary releases. The Company used $19.5 million in insurance proceeds to fund the settlement. The Company previously filed a lawsuit in Delaware state court against certain of its insurers for full payment of its liabilities related to this securities litigation. The Company intends to oppose any efforts by the carrier defendants to recoup insurance proceeds that they have advanced to date.

Shareholder derivative actions parallel to the securities class action have also been filed, naming Clover as a nominal defendant. The first action was filed in the United States District Court for the District of Delaware and is captioned Furman v. Garipalli, et al., Case No. 1:21-cv-00191 (D. Del.). The complaint asserts violations of sections 10(b) and 21D of the Exchange Act, breach of fiduciary duty, and waste of corporate assets against certain of the Company's directors. It seeks unspecified damages and an order requiring Clover to take certain actions to enhance Clover's corporate governance policies, and procedures. The second and third actions were filed in the United States District Court for the Middle District of Tennessee and are captioned Sun v. Garipalli, et al., Case No. 3:21-cv-00311 (M.D. Tenn.), and Luthra v. Garipalli, et al., Case No. 3:21-cv-00320 (M.D. Tenn.). The complaints assert violations of section 14(a) of the Exchange Act, breach of fiduciary duty, and aiding and abetting a breach of fiduciary duty. The Sun action also asserts unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution under section 11(f) of the Securities Act, and sections 10(b) and 21D of the Exchange Act. The complaints name certain current and former officers and directors as defendants. They seek unspecified damages and an order requiring Clover to take certain actions to enhance Clover's corporate governance policies and procedures.

The fourth action was filed in the United States District of Delaware and is captioned Wiegand v. Garipalli, et al., Case No. 1:21-cv-01053 (D. Del.). The initial complaint asserted violations of sections 14(a) and 20(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste of corporate assets. The complaint names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages and an order requiring Clover to take certain actions to improve Clover's corporate governance and internal procedures. The fifth action was filed in the Supreme Court of the State of New York and is captioned Sankaranarayanan v. Palihapitiya, et al., Index No. 655420/2021 (N.Y. Sup. Ct., N.Y. Cnty.). The complaint asserts breach of fiduciary duty and unjust enrichment. The complaint names certain former officers and directors as defendants. It seeks, among other things, unspecified damages and an order directing Clover to take certain actions to reform and improve its corporate governance and internal procedures.

---

The sixth action was filed in the Delaware Court of Chancery and is captioned Davies v. Garipalli, et al., No. 2021-1016-SG (Del. Ch.). The complaint asserts breach of fiduciary duty. The complaint names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages and an order directing Clover to take certain actions to reform and improve its corporate governance and internal procedures. The seventh action was filed in the Supreme Court of the State of New York and is captioned Uvaydov v. Palihapitiya, et al., Index No. 656978/2021 (N.Y Sup. Ct., N.Y. Cnty.). The complaint asserts breach of fiduciary duty, unjust enrichment, and aiding and abetting a breach of fiduciary duty. The complaint names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages, restitution, and disgorgement of profits obtained by defendants.

On May 10, 2021, the Middle District of Tennessee shareholder derivative actions described above were consolidated under Sun v. Garipalli, et al., Case No. 3:21-cv-00311 (M.D. Tenn.) as lead case. On November 30, 2021, the Sun and Luthra plaintiffs filed an amended complaint, asserting violations of section 14(a) of the Exchange Act, breach of fiduciary duty, aiding and abetting a breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution under sections 10(b) and 21D of the Exchange Act. The amended complaint generally relates to the allegations published in the Hindenburg Article, and names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages and an order requiring Clover to take certain actions to enhance Clover's corporate governance policies and procedures.

On September 16, 2021, the two District of Delaware derivative actions were consolidated under In re Clover Health Investments, Corp. Derivative Litigation, Case No. 1:21-cv-00191-LPS (Consolidated). The Furman complaint was deemed the operative complaint. On April 19, 2022, the plaintiff in the Wiegand action filed an amended complaint, asserting violations of Sections 10(b), 20(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment against certain current and former officers and directors. The amended complaint seeks, among other things, unspecified damages and an order requiring Clover to take certain actions to improve Clover's corporate governance and internal procedures.

On August 19, 2022, the two derivative actions filed in New York state court were consolidated under In re Clover Health Investments, Corp. Stockholder Derivative Litig., Index No. 655420/2021. On November 3, 2022, the plaintiffs in this action filed a consolidated complaint, asserting breach of fiduciary duty, and unjust enrichment, and naming certain former officers and directors as defendants. The complaint seeks, among other things, unspecified damages, restitution, the disgorgement of profits obtained by defendants, and an order directing Clover to take certain actions to reform and improve its corporate governance and internal procedures.

On June 21, 2023, the plaintiffs in the derivative lawsuits, on the one hand, and the Company, on the other hand, entered into a binding memorandum of understanding providing for the settlement of the derivative actions. On February 5, 2024, the parties executed a stipulation of settlement which, subject to final court approval, will provide the defendants in the derivative lawsuits with customary releases and will require the Company to implement a suite of corporate governance enhancements. On July 11, 2024, the United States District Court for the Middle District of Tennessee entered a final judgment approving the settlement. The settlement does not involve any monetary payment, other than payment of an award of fees and expenses to plaintiffs’ counsel in the amount of $2,500,000.

Bylaw Litigation

On March 26, 2024, a putative shareholder filed a class action suit against the Company and its directors and officers in Delaware Chancery Court challenging a Company bylaw governing the process for nominating a candidate to the board of directors as preclusive and coercive. The case is captioned Taylor v. Clinton, et al., Case No. 2024-0305 (Del. Ch.). In June 2024, the Company adopted an amendment to its bylaws mooting the litigation, and the plaintiffs voluntarily dismissed the suit, with the court retaining jurisdiction solely for the purpose of determining plaintiffs’ counsel’s application for attorneys’ fees and reimbursement (the “Fee Application”). On October 23, 2024, solely to avoid the time and expense of continued litigation, the Company and the plaintiffs agreed to resolve the Fee Application in exchange for a payment by the Company of $250,000 to Plaintiff’s counsel. The case is now closed.

---

Starting in 2024, the Company manages its operations based on one reportable operating segment: Insurance. Through the Insurance segment, the Company provides PPO and HMO plans to Medicare Advantage members in several states. These segment groupings are consistent with information used by the CODM, to assess performance and allocate resources.

The operations of the Company are organized into the following segment:

•Insurance Segment includes operations related to the Company's MA plans, which generally provide access to a wide network of primary care providers, specialists, and hospitals.

Corporate/Other includes other clinical services not included in Medicare Advantage, Counterpart Health, and all other corporate overhead. Clinical services is comprised of Clover Care Services and other clinical services that are offered to eligible beneficiaries.

The table below summarizes the Company's results by operating segment:

						Insurance						Corporate/Other						Eliminations						Consolidated Total
Three months ended September 30, 2024						(in thousands)
Premiums earned, net (net of ceded premiums of $97)						$	322,579					$	—					$	—					$	322,579
Other income						4,314						32,422						(28,329)						8,407
Intersegment revenues						—						46,944						(46,944)						—
Net medical claims incurred						251,643						4,442						(6,311)						249,774
Gross profit						$	75,250					$	74,924					$	(68,962)					$	81,212
Total assets						$	408,381					$	918,407					$	(673,775)					$	653,013
						Insurance						Corporate/Other						Eliminations						Consolidated Total
Nine months ended September 30, 2024						(in thousands)
Premiums earned, net (net of ceded premiums of $301)						$	1,014,201					$	—					$	—					$	1,014,201
Other income						12,085						90,371						(82,489)						19,967
Intersegment revenues						—						146,608						(146,608)						—
Net medical claims incurred						767,125						14,345						(18,187)						763,283
Gross profit						$	259,161					$	222,634					$	(210,910)					$	270,885
Total assets						$	408,381					$	918,407					$	(673,775)					$	653,013

---

						Insurance						Corporate/Other						Eliminations						Consolidated Total
Three months ended September 30, 2023						(in thousands)
Premiums earned, net (net of ceded premiums of $106)						$	301,230					$	—					$	—					$	301,230
Other income						3,338						14,218						(12,758)						4,798
Intersegment revenues						—						43,335						(43,335)						—
Net medical claims incurred						236,533						4,690						(5,438)						235,785
Gross profit						$	68,035					$	52,863					$	(50,655)					$	70,243
Total assets						$	464,942					$	905,477					$	(685,439)					$	684,980
						Insurance						Corporate/Other						Eliminations						Consolidated Total
Nine months ended September 30, 2023						(in thousands)
Premiums earned, net (net of ceded premiums of $341)						$	932,699					$	—					$	—					$	932,699
Other income						7,192						45,732						(37,465)						15,459
Intersegment revenues						—						112,220						(112,220)						—
Net medical claims incurred						753,877						11,820						(10,861)						754,836
Gross profit						$	186,014					$	146,132					$	(138,824)					$	193,322
Total assets						$	464,942					$	905,477					$	(685,439)					$	684,980

A reconciliation of the reportable segments' gross profit to the Net loss from continuing operations included in the Condensed Consolidated Statements of Operations and Comprehensive Loss is as follows:

						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
						(in thousands)
Gross profit						$	81,212					$	70,243					$	270,885					$	193,322
Salaries and benefits						54,995						60,567						169,717						191,985
General and administrative expenses						35,201						41,030						124,194						140,384
Premium deficiency reserve expense (benefit)						—						392						—						(6,556)
Depreciation and amortization						339						557						987						1,835
Restructuring (recoveries) costs						(538)						1,313						288						7,870
Change in fair value of warrants						—						—						17						—
Interest expense						—						—						—						7
Loss on investment						—						—						467						—
Net loss from continuing operations						$	(8,785)					$	(33,616)					$	(24,785)					$	(142,203)

The Company's regulated insurance subsidiaries are subject to regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital and limit the timing and amount of dividends and other distributions that may be paid to their parent companies. Therefore, the Company's regulated insurance subsidiaries' ability to declare and pay dividends is limited by state regulations including obtaining prior approval by the New Jersey Department of Banking and Insurance. At September 30, 2024 and December 31, 2023, neither of the regulated insurance subsidiaries had been authorized nor paid any dividends.

---

On April 17, 2023, the Company announced it would implement certain business transformation initiatives, including an agreement to move its core MA operational platform to UST HealthProof’s (“UST HealthProof”) and additional corporate restructuring actions. The agreement with UST HealthProof includes the transition of certain of the Company’s plan operation functions in support of its Medicare Advantage members pursuant to a master services agreement. In addition to the arrangement with UST HealthProof, in April 2023 the Company conducted a reduction in force to better align its Selling, General, and Administrative cost structure with its revenue base. This restructuring resulted in the elimination of approximately 10% of the Company's workforce. The Company incurred costs related to these business transformation initiatives, which consisted of employee termination benefits, vendor related costs, and other costs, which are accounted for as exit and disposal costs and recorded pursuant to ASC 420, Exit or Disposal Cost Obligations. For those costs determined to be one-time termination benefits the Company established a liability for the restructuring related expenses when the plan was established, the remaining costs will be expensed as incurred.

The Restructuring costs are presented in the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss, which were as follows:

						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
						(in thousands)
Employee termination (recoveries) benefits						$	(547)					$	58					$	(547)					$	4,620
Vendor related costs						—						1,245						822						3,166
Other						9						10						13						84
Total restructuring (recoveries) costs						$	(538)					$	1,313					$	288					$	7,870

UST HealthProof Transition

As of September 30, 2024, the liability for employee termination benefits was recorded in Accrued salaries and benefits and the liability for vendor related costs and other expenses were recorded in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. The liability recorded reflects the Company's best estimate, which may be revised in subsequent periods as the restructuring progresses. The restructuring costs are recorded within the Corporate/Other operating segment. In addition, the Company incurred costs related to software impairment. These costs are recognized in Depreciation and amortization in the Condensed Consolidated Statements of Operations and Comprehensive Loss, and totaled less than $0.1 million for the three months and nine months ended September 30, 2024. For the three and nine months ended September 30, 2023, software impairment costs totaled $0.1 million.

						Employee Termination Benefits						Vendor related costs						Other						Total
						(in thousands)
Liability as of December 31, 2023						$	1,781					$	3,390					$	—					$	5,171
(Recoveries) charges						(547)						822						13						288
Cash payments						(1,234)						(1,307)						(13)						(2,554)
Liability as of September 30, 2024						$	—					$	2,905					$	—					$	2,905
Total cumulative costs incurred as of September 30, 2024						$	4,248					$	5,761					$	100					$	10,109

---

On December 1, 2023, the Company notified CMS that it would no longer participate as a REACH ACO in connection with the 2024 performance year. The Company’s exit from the ACO REACH Program was made after the Company determined that it is in its best interest to fully exit the ACO REACH Program starting with the 2024 performance year, and follows the Company's November 2022 announcement of a strategic reduction in the number of ACO REACH participating physicians in 2023. The nature of the remaining activities relate to the settlement with CMS related to prior performance years which is expected to be completed by the end of 2024.

A summary of the carrying amounts of major assets and liabilities, which were classified as held for settlement in the Condensed Consolidated Balance Sheets, follows:

			September 30, 2024						December 31, 2023
			(in thousands)
Assets(1)
Cash and cash equivalents			$	—					$	6,456
Surety bond and deposits			—						55,089
Non-Insurance receivable			10,087						10,926
Total assets			$	10,087					$	72,471
Liabilities(1)
Unpaid claims			$	1,080					$	2,856
Accrued salaries and benefits			—						110
Non-Insurance performance year obligation, current			4,740						15,568
Non-Insurance payable			43,121						41,565
Total liabilities			$	48,941					$	60,099

(1) The assets and liabilities of the disposal group are classified as current in the Condensed Consolidated Balance Sheet at September 30, 2024 as the settlement with CMS is expected to occur within one year.

A summary of the results from discontinued operations included in the Condensed Consolidated Statements of Operations and Comprehensive Loss follows:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
			(in thousands)
Revenues:
Non-Insurance revenue			$	(6,149)					$	176,038					$	(370)					$	575,311
Total revenues			(6,149)						176,038						(370)						575,311
Operating Expenses:
Net medical claims incurred			(6,009)						183,174						(5,276)						573,567
General and administrative expenses			230						717						741						2,430
Restructuring costs			—						—						297						—
Total operating expenses			(5,779)						183,891						(4,238)						575,997
(Loss) gain from operations			(370)						(7,853)						3,868						(686)
Net (loss) income			$	(370)					$	(7,853)					$	3,868					$	(686)

---

A summary of cash flows from discontinued operations included in the Condensed Consolidated Statements of Cash Flows follows:

			Nine Months Ended September 30,
			2024						2023
			(in thousands)
Net cash (used in) provided by operating activities			$	(8,861)					$	34,060

Performance guarantees

Certain of the Company's arrangements with third-party providers require it to guarantee the performance of its care network to CMS. As a result of the Company's participation in the ACO REACH Model, the Company determined that it was making a performance guarantee with respect to providers under the Non-Insurance arrangement that should be recognized in the financial statements. The performance guarantee identified relates to the Company guaranteeing the performance of the third-party medical providers. Thus, the contract with CMS is accounted for as a performance guarantee under ASC 460, Guarantees. At the inception of the performance year, the Company measures and recognizes the performance guarantee receivable and obligation, issued in this standalone arm's length transaction, using the practical expedient to fair value as set forth in ASC 460-10-30-2(a). The Company estimates the annualized benchmark, which is the amount recognized in both the Non-Insurance performance year receivable and the Non-Insurance performance year obligation, current. This is consistent with ASC 460-10-25-4, which provides that a guarantor shall recognize in its statement of financial position a liability for that guarantee. In addition, when the guarantee is issued in a standalone transaction for a premium, the offsetting entry should be considered received (such as cash or a receivable) according to ASC 460-10-25-4. Thus the Company recognizes the Non-Insurance performance year receivable on its balance sheets.

To subsequently measure and recognize the performance guarantee, the Company follows ASC 460-10-35-2(b) and applies a systematic and rational approach to reflect its release from risk. Under this approach, the Company amortizes on a straight-line basis over the performance year, the obligation. The Company has determined this systematic and rational method is appropriate, as it matches the period in which the guarantee is fulfilled. In addition, ASC 460-10-35-2 provides further guidance on the subsequent measurement related to the Company's performance guarantee. Per ASC 460-10-35-2, depending on the nature of the guarantee, the guarantor's release from risk typically can be recognized over the term of the guarantee using one of three methods: (1) upon expiration or settlement, (2) by systematic or rational amortization, or (3) as the fair value of the guarantee changes. The Company has determined that method (2) is the appropriate method of recognition as discussed above.

With respect to each performance year in which the ACO is a participant, the final consideration due to the ACO from CMS ("shared savings") or the consideration due to CMS from the ACO ("shared loss") is reconciled in the subsequent years following the performance year. The shared savings or loss is measured periodically and will be applied to the Non-Insurance performance obligation, current or Non-Insurance performance receivable if the Company is in a probable loss position or probable savings position, respectively. The ACO has entered into an agreement with CMS and a third-party to cover the financial threshold determined by CMS.

In April 2021, the Company began participating in the Global and Professional Direct Contracting of the Centers for Medicare & Medicaid Services ("CMS"), which utilizes a structured model intended to reduce expenditures and preserve or enhance quality of care for people with Medicare fee-for-service ("FFS"). CMS rebranded the DC Model and renamed the model the ACO Realizing Equity, Access, and Community Health (REACH) Model ("ACO REACH Model") effective January 1, 2023. As a participating entity in the DC Model, referred to as the ACO REACH Model at January 1, 2023, with a global risk arrangement, the Company assumed the responsibility of guaranteeing the performance of its care network. The ACO REACH Model is intended to reduce administrative burden and support a focus on complex, chronically ill patients. On December 1, 2023, the Company notified CMS that it will no longer participate as a REACH ACO in connection with the 2024 performance year. The Company’s exit from the ACO REACH Program was made after the Company determined that it is in the Company's best interest to fully exit the ACO REACH Program, and follows its November 2022 announcement of a strategic reduction in the number of ACO REACH participating physicians in 2023.

Certain of the Company's arrangements with third-party providers require it to guarantee the performance of its care network to CMS, which, if not obtained, could potentially result in payment to CMS. The Non-Insurance performance year obligation and receivable are amortized on a straight-line basis for the amount that represents the completed performance. The Company is unable to estimate the maximum potential amount of future payments under the guarantee. This is attributable to the stop-loss arrangement and the corridors (tiered levels) in the arrangement. A certain percentage of these arrangements will still be the responsibility of the Company, in addition to a number of variables that are not reasonable for the Company to estimate, such as, but not limited to, risk ratings and benchmark trends that have an inestimable impact on the estimate of future payments.

For additional information, see Note 2 (Summary of Significant Accounting Policies) and Note 20 (Non-Insurance) in the 2023 Form 10-K.

---

The tables below include the financial statement impacts of the performance guarantee:

						September 30, 2024						December 31, 2023
						(in thousands)
Non-Insurance performance year obligation (1)						$	4,740					$	15,568
(1) This obligation represents the consideration due to providers, net of the shared savings or loss for the period and amortization of the liability.

						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
						(in thousands)
Amortization of the Non-Insurance performance year receivable						$	—					$	(182,753)					$	—					$	(556,211)
Amortization of the Non-Insurance performance year obligation						—						182,753						—						556,211
Non-Insurance revenue						(6,149)						176,038						(370)						575,311

---

---

---

---

---

---

---

---

---

---

---

---

---

---

v3.24.3

Cover - shares	9 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-39252
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-1515192
Entity Address, Address Line One	3401 Mallory Lane
Entity Address, Address Line Two	Suite 210
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	201
Local Phone Number	432-2133
Title of 12(g) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	CLOV
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001801170
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity Registrant Name	CLOVER HEALTH INVESTMENTS, CORP. /DE
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		412,076,431
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		89,032,605

v3.24.3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 287,956	$ 116,407
Short-term investments	1,779	12,218
Investment securities, available-for-sale (Amortized cost: 2024: $43,695; 2023: $101,412)	43,302	100,702
Investment securities, held-to-maturity (Fair value: 2024: $15; 2023: $6,778)	15	6,902
Accrued retrospective premiums	20,963	22,076
Other receivables	14,962	16,666
Healthcare receivables	37,314	64,164
Surety bonds and deposits	596	542
Prepaid expenses	12,949	14,418
Other assets, current	2,804	1,404
Assets related to discontinued operations (Note 17)	10,087	72,471
Total current assets	432,727	427,970
Investment securities, available-for-sale (Amortized cost: 2024: $182,840; 2023: $121,868)	184,085	120,208
Investment securities, held-to-maturity (Fair value: 2024: $14,178; 2023: $692)	14,294	793
Property and equipment, net	5,336	5,082
Operating lease right-of-use assets	2,585	3,382
Other intangible assets	2,990	2,990
Other assets, non-current	10,996	10,246
Total assets	653,013	570,671
Current liabilities
Unpaid claims	166,070	135,737
Accounts payable and accrued expenses	25,746	37,184
Accrued salaries and benefits	35,340	20,951
Deferred revenue	17	3,099
Operating lease liabilities	1,345	1,665
Liabilities related to discontinued operations (Note 17)	48,941	60,099
Total current liabilities	279,635	261,115
Long-term operating lease liabilities	2,321	2,998
Other liabilities, non-current	28,891	20,164
Total liabilities	310,847	284,277
Commitments and contingencies (Note 13)
Stockholders' equity
Additional paid-in capital	2,546,167	2,461,238
Accumulated other comprehensive income (loss)	852	(2,370)
Accumulated deficit	(2,180,711)	(2,159,794)
Less: Treasury stock, at cost; 16,817,010 and 7,912,750 shares held at September 30, 2024 and December 31, 2023, respectively	(24,192)	(12,729)
Total stockholders' equity	342,166	286,394
Total liabilities and stockholders' equity	653,013	570,671
Common Class A
Stockholders' equity
Common stock, value	41	40
Common Class B
Stockholders' equity
Common stock, value	9	9
Related party
Current liabilities
Due to related parties, net	1,340	1,363
Other liabilities, current	1,340	1,363
Nonrelated party
Current liabilities
Due to related parties, net	836	1,017
Other liabilities, current	$ 836	$ 1,017

v3.24.3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Investment securities, available-for sale, amortized cost current	$ 43,695	$ 101,412
Investment securities, held-to-maturity, fair value current	15	6,778
Investment securities, available-for sale, amortized cost noncurrent	182,840	121,868
Investment securities, held-to-maturity, fair value noncurrent	$ 14,178	$ 692
Treasury stock, shares held (in shares)	16,817,010	7,912,750
Common Class A
Common stock, par value, (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	2,500,000,000	2,500,000,000
Common stock, shares, issued (in shares)	411,256,965	401,183,882
Common stock, shares, outstanding (in shares)	411,256,965	401,183,882
Common Class B
Common stock, par value, (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares, issued (in shares)	89,032,305	87,867,732
Common stock, shares, outstanding (in shares)	89,032,305	87,867,732

v3.24.3

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Premiums earned, net (Net of ceded premiums of $97 and $106 for the three months ended September 30, 2024 and 2023, respectively; net of ceded premiums of $301 and $341 for the nine months ended September 30, 2024 and 2023, respectively)	$ 322,579	$ 301,230	$ 1,014,201	$ 932,699
Other income	8,407	4,798	19,967	15,459
Total revenues	330,986	306,028	1,034,168	948,158
Operating expenses:
Net medical claims incurred	249,774	235,785	763,283	754,836
Salaries and benefits	54,995	60,567	169,717	191,985
General and administrative expenses	35,201	41,030	124,194	140,384
Premium deficiency reserve expense (benefit)	0	392	0	(6,556)
Depreciation and amortization	339	557	987	1,835
Restructuring (recoveries) costs	(538)	1,313	288	7,870
Total operating expenses	339,771	339,644	1,058,469	1,090,354
Loss from continuing operations	(8,785)	(33,616)	(24,301)	(142,196)
Change in fair value of warrants	0	0	17	0
Interest expense	0	0	0	7
Loss on investment	0	0	467	0
Net loss from continuing operations	(8,785)	(33,616)	(24,785)	(142,203)
Net (loss) income from discontinued operations (Note 17)	(370)	(7,853)	3,868	(686)
Net loss	$ (9,155)	$ (41,469)	$ (20,917)	$ (142,889)
Per share data:
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	490,180,103	480,770,283	488,501,812	480,921,520
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	490,180,103	480,770,283	488,501,812	480,921,520
Continuing operations:
Basic loss per share (in dollars per share)	$ (0.02)	$ (0.07)	$ (0.05)	$ (0.30)
Diluted loss per share (in dollars per share)	(0.02)	(0.07)	(0.05)	(0.30)
Discontinued operations:
Basic earnings (loss) per share (in dollars per share)	0.00	(0.02)	0.01	0.00
Diluted earnings (loss) per share (in dollars per share)	$ 0.00	$ (0.02)	$ 0.01	$ 0.00
Net unrealized gain on available-for-sale investments	$ 3,111	$ 1,643	$ 3,222	$ 4,302
Comprehensive loss	$ (6,044)	$ (39,826)	$ (17,695)	$ (138,587)

v3.24.3

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Ceded premiums	$ 97	$ 106	$ 301	$ 341

v3.24.3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Previously Reported	Change in accounting policy	Treasury Stock	Treasury Stock Previously Reported	Additional paid-in capital	Additional paid-in capital Previously Reported	Accumulated deficit	Accumulated deficit Previously Reported	Accumulated deficit Change in accounting policy	Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss) Previously Reported	Common Class A	Common Class A Common stock	Common Class A Common stock Previously Reported	Common Class A Common stock RSUs	Common Class B	Common Class B Common stock	Common Class B Common stock Previously Reported	Common Class B Common stock RSUs
Beginning balance (in shares) at Dec. 31, 2022															383,998,718				94,394,852
Beginning balance (in shares) at Dec. 31, 2022					2,072,752
Beginning balance at Dec. 31, 2022		$ 347,738	$ 9,149		$ (6,509)		$ 2,319,157		$ (1,955,582)	$ 9,149		$ (9,374)			$ 37				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance for exercise of stock options, net of early exercise liability (in shares)														1,240
Stock issuance for exercise of stock options, net of early exercise liability	$ 848					$ 848
Stock-based compensation	38,617					38,617
Vested restricted stock units (in shares)																5,390,973				1,773,104
Unrealized holdings gain on investment securities, available for sale	2,343										$ 2,343
Conversion from Class B Common Stock to Class A Common Stock (in shares)														7,672,463				(7,672,463)
Treasury stock acquired (in shares)				2,933,721										(2,933,721)
Treasury stock acquired	(2,982)			$ (2,982)
Net loss	(72,606)							$ (72,606)
Ending balance (in shares) at Mar. 31, 2023														394,129,673				88,495,493
Ending balance (in shares) at Mar. 31, 2023				5,006,473
Ending balance at Mar. 31, 2023	323,107			$ (9,491)		2,358,622		(2,019,039)			(7,031)			$ 37				$ 9
Beginning balance (in shares) at Dec. 31, 2022															383,998,718				94,394,852
Beginning balance (in shares) at Dec. 31, 2022					2,072,752
Beginning balance at Dec. 31, 2022		$ 347,738	$ 9,149		$ (6,509)		$ 2,319,157		$ (1,955,582)	$ 9,149		$ (9,374)			$ 37				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized holdings gain on investment securities, available for sale	4,302
Ending balance (in shares) at Sep. 30, 2023														399,374,685				87,867,732
Ending balance (in shares) at Sep. 30, 2023				7,096,160
Ending balance at Sep. 30, 2023	321,852			$ (11,902)		2,428,101		(2,089,322)			(5,072)			$ 38				$ 9
Beginning balance (in shares) at Mar. 31, 2023														394,129,673				88,495,493
Beginning balance (in shares) at Mar. 31, 2023				5,006,473
Beginning balance at Mar. 31, 2023	323,107			$ (9,491)		2,358,622		(2,019,039)			(7,031)			$ 37				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance for exercise of stock options, net of early exercise liability (in shares)														1,241
Stock issuance for exercise of stock options, net of early exercise liability	270					270
Stock-based compensation	36,108					36,108
Vested restricted stock units (in shares)																1,180,084
Unrealized holdings gain on investment securities, available for sale	316										316
Conversion from Class B Common Stock to Class A Common Stock (in shares)														627,761				(627,761)
Treasury stock acquired (in shares)				439,241										(439,241)
Treasury stock acquired	(417)			$ (417)
Issuance of common stock under Employee Stock Purchase Plan (in shares)														271,152
Net loss	(28,814)							(28,814)
Ending balance (in shares) at Jun. 30, 2023														395,770,670				87,867,732
Ending balance (in shares) at Jun. 30, 2023				5,445,714
Ending balance at Jun. 30, 2023	330,570			$ (9,908)		2,395,000		(2,047,853)			(6,715)			$ 37				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance for exercise of stock options, net of early exercise liability (in shares)														76,156
Stock issuance for exercise of stock options, net of early exercise liability	31					31
Stock-based compensation	33,070					33,070
Vested restricted stock units (in shares)																5,178,305
Vested restricted stock units	1													$ 1
Unrealized holdings gain on investment securities, available for sale	1,643										1,643
Treasury stock acquired (in shares)				1,650,446										(1,650,446)
Treasury stock acquired	(1,994)			$ (1,994)
Net loss	(41,469)							(41,469)
Ending balance (in shares) at Sep. 30, 2023														399,374,685				87,867,732
Ending balance (in shares) at Sep. 30, 2023				7,096,160
Ending balance at Sep. 30, 2023	$ 321,852			$ (11,902)		2,428,101		(2,089,322)			(5,072)			$ 38				$ 9
Beginning balance (in shares) at Dec. 31, 2023													401,183,882	401,183,882			87,867,732	87,867,732
Beginning balance (in shares) at Dec. 31, 2023	7,912,750			7,912,750
Beginning balance at Dec. 31, 2023	$ 286,394			$ (12,729)		2,461,238		(2,159,794)			(2,370)			$ 40				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance for exercise of stock options, net of early exercise liability (in shares)														83
Stock-based compensation	28,798					28,798
Vested restricted stock units (in shares)																8,672,362				1,781,633
Vested restricted stock units	1													$ 1
Unrealized holdings gain on investment securities, available for sale	(190)										(190)
Treasury stock acquired (in shares)				3,700,995										(3,700,995)
Treasury stock acquired	(3,359)			$ (3,359)
Net loss	(19,170)							(19,170)
Ending balance (in shares) at Mar. 31, 2024														406,155,332				89,649,365
Ending balance (in shares) at Mar. 31, 2024				11,613,745
Ending balance at Mar. 31, 2024	$ 292,474			$ (16,088)		2,490,036		(2,178,964)			(2,560)			$ 41				$ 9
Beginning balance (in shares) at Dec. 31, 2023													401,183,882	401,183,882			87,867,732	87,867,732
Beginning balance (in shares) at Dec. 31, 2023	7,912,750			7,912,750
Beginning balance at Dec. 31, 2023	$ 286,394			$ (12,729)		2,461,238		(2,159,794)			(2,370)			$ 40				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized holdings gain on investment securities, available for sale	$ 3,222
Repurchases of Common Stock (in shares)	1,838,309
Repurchases of Common Stock	$ (1,800)
Ending balance (in shares) at Sep. 30, 2024													411,256,965	411,256,965			89,032,305	89,032,305
Ending balance (in shares) at Sep. 30, 2024	16,817,010			16,817,010
Ending balance at Sep. 30, 2024	$ 342,166			$ (24,192)		2,546,167		(2,180,711)			852			$ 41				$ 9
Beginning balance (in shares) at Mar. 31, 2024														406,155,332				89,649,365
Beginning balance (in shares) at Mar. 31, 2024				11,613,745
Beginning balance at Mar. 31, 2024	292,474			$ (16,088)		2,490,036		(2,178,964)			(2,560)			$ 41				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance for exercise of stock options, net of early exercise liability (in shares)														61,212
Stock issuance for exercise of stock options, net of early exercise liability	23					23
Stock-based compensation	27,900					27,900
Vested restricted stock units (in shares)																3,003,054
Unrealized holdings gain on investment securities, available for sale	301										301
Treasury stock acquired (in shares)				1,122,347										(1,122,347)
Treasury stock acquired	(1,446)			$ (1,446)
Issuance of common stock under Employee Stock Purchase Plan (in shares)														227,502
Repurchases of Common Stock (in shares)				1,838,309										(1,838,309)
Repurchases of Common Stock	(1,772)			$ (1,772)
Net loss	7,408							7,408
Ending balance (in shares) at Jun. 30, 2024														406,486,444				89,649,365
Ending balance (in shares) at Jun. 30, 2024				14,574,401
Ending balance at Jun. 30, 2024	324,888			$ (19,306)		2,517,959		(2,171,556)			(2,259)			$ 41				$ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issuance for exercise of stock options, net of early exercise liability (in shares)														122,662
Stock issuance for exercise of stock options, net of early exercise liability	220					220
Stock-based compensation	27,988					27,988
Vested restricted stock units (in shares)																6,273,408
Vested restricted stock units	0
Unrealized holdings gain on investment securities, available for sale	3,111										3,111
Conversion from Class B Common Stock to Class A Common Stock (in shares)														617,060				(617,060)
Treasury stock acquired (in shares)				2,242,609										(2,242,609)
Treasury stock acquired	(4,886)			$ (4,886)
Net loss	$ (9,155)							(9,155)
Ending balance (in shares) at Sep. 30, 2024													411,256,965	411,256,965			89,032,305	89,032,305
Ending balance (in shares) at Sep. 30, 2024	16,817,010			16,817,010
Ending balance at Sep. 30, 2024	$ 342,166			$ (24,192)		$ 2,546,167		$ (2,180,711)			$ 852			$ 41				$ 9

v3.24.3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (9,155)	$ (41,469)	$ (20,917)	$ (142,889)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	339	557	987	1,835
Stock-based compensation			84,686	107,795
Change in fair value of warrants and amortization of warrants			17	0
Accretion, net of amortization			(2,140)	(3,096)
Accrued interest earned			(354)	0
Net realized gains on investment securities			(174)	(20)
Loss on investment	0	0	467	0
Premium deficiency reserve	0	392	0	(6,556)
Changes in operating assets and liabilities:
Accrued retrospective premiums			1,113	4,741
Other receivables			1,704	8,836
Surety bonds and deposits			(54)	(17)
Prepaid expenses			1,469	2,920
Other assets			(2,640)	5,244
Healthcare receivables			26,850	18,534
Operating lease right-of-use assets			797	405
Unpaid claims			30,310	(24,164)
Accounts payable and accrued expenses			(11,438)	2,851
Accrued salaries and benefits			14,389	371
Deferred revenue			(3,082)	103,295
Other liabilities			8,546	179
Operating lease liabilities			(997)	(900)
Net cash provided by operating activities from continuing operations			129,539	79,364
Net cash (used in) provided by operating activities from discontinued operations (Note 17)			(8,861)	34,060
Net cash provided by operating activities			120,678	113,424
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities			(153,347)	(142,359)
Proceeds from sales of short-term investments and available-for-sale securities	47,804	0	47,804	60,436
Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities	42,137	32,240	108,788	139,122
Purchases of property and equipment			(1,241)	(848)
Net cash provided by investing activities			2,004	56,351
Cash flows from financing activities:
Issuance of common stock, net of early exercise liability			243	1,149
Repurchases of common stock			(1,772)	0
Treasury stock acquired			(9,691)	(5,393)
Net cash used in financing activities			(11,220)	(4,244)
Net increase in cash, cash equivalents, and restricted cash for discontinued and continuing operations			111,462	165,531
Cash, cash equivalents, and restricted cash, beginning of period for discontinued and continuing operations			176,494	186,213
Cash, cash equivalents, and restricted cash, end of period for discontinued and continuing operations	287,956	351,744	287,956	351,744
Reconciliation of cash and cash equivalents and restricted cash for discontinued and continuing operations
Cash and cash equivalents	287,956	299,014	287,956	299,014
Restricted cash	0	52,730	0	52,730
Total cash, cash equivalents, and restricted cash for discontinued and continuing operations	$ 287,956	$ 351,744	287,956	351,744
Supplemental disclosure of non-cash activities
Performance year receivable			0	(185,404)
Performance year obligation			$ 0	$ 185,404

v3.24.3

Organization and Operations	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Organization and Operations Clover Health Investments, Corp. (collectively with its affiliates and subsidiaries, "Clover" or the "Company") is focused on empowering physicians to identify and manage chronic diseases early. Clover has centered its strategy on building and deploying technology through its flagship software platform, Clover Assistant, to help America's seniors receive better care at lower costs. Clover aims to provide affordable, high-quality Medicare Advantage plans, including Preferred Provider Organization ("PPO") and Health Maintenance Organization ("HMO") plans, through its regulated insurance subsidiaries. The Company's regulated insurance subsidiaries consist of Clover Insurance Company and Clover HMO of New Jersey Inc., which operate the Company's PPO and HMO health plans, respectively. On April 1, 2021, the Company's subsidiary, Clover Health Partners, LLC ("Health Partners"), began participating as a Direct Contracting Entity ("DCE") in the Global and Professional Direct Contracting Model ("DC Model") of the Centers for Medicare and Medicaid Services ("CMS"), an agency of the United States Department of Health and Human Services, through which the Company had previously provided care to aligned Medicare fee-for-service ("FFS") beneficiaries (the "Non-Insurance Beneficiaries") through our prior participation in ACO REACH Program, as defined herein. CMS redesigned the DC Model and renamed it the Accountable Care Organization ("ACO") Realizing Equity, Access, and Community Health ("REACH") ("ACO REACH") Model effective January 1, 2023. On December 1, 2023, the Company notified CMS that it will no longer participate as a REACH ACO in the CMS ACO Reach Program, effective as of the end of the 2023 performance year. The Company’s exit from the ACO REACH Program follows its November 2022 announcement of a strategic reduction in the number of ACO REACH participating physicians in 2023, and was made after the Company determined that it is in the Company's best interest to fully exit the ACO REACH Program starting with the 2024 performance year. The activity recognized during 2024 relates to prior performance years with CMS and are presented in discontinued operations for all periods presented in the condensed consolidated financial statements. See Note 17 for further discussion of discontinued operations. Medical Service Professionals of NJ, LLC, houses Clover's employed physicians and the related support staff for Clover's in-home care program. Clover's administrative functions and insurance operations are primarily operated by its Clover Health, LLC and Clover Health Labs, LLC subsidiaries. For any information following the aforementioned paragraph, the Company will refer to its participation in ACO REACH Model or the Company's participation in the predecessor DC Model as ACO REACH Model henceforth. Clover's approach is to combine technology, data analytics, and preventive care to lower costs and increase the quality of health and life of Medicare beneficiaries. Clover's technology platform is designed to use machine learning-powered systems to deliver data and insights to physicians in order to improve outcomes for beneficiaries through the early identification and management of chronic disease and drive down costs. Clover's MA plans generally provide access to a wide network of primary care providers, specialists, and hospitals, enabling its members to see any doctor participating in Medicare willing to accept them. Clover focuses on minimizing members' out-of-pocket costs and offers many plans that allow members to pay the same co-pays for primary care provider visits regardless of whether their physician is in- or out-of-network. During the second quarter of 2024, the Company launched Counterpart Health, Inc., a new Software-as-a-Service (“SaaS”) and Tech Enabled Services Solution to bring the power of CA Technology to Medicare Advantage payors and providers. This external offering aims to equip clinician users with the Company's already built, clinician-centric, and AI-powered care management platform. Strategically, Counterpart Health, Inc., a subsidiary of Clover Health, aims to extend the benefits of data-driven proven technology and personalized care to a wider audience, enabling enhanced patient outcomes and reduced healthcare costs across the nation. Counterpart Health is complementary to Clover Health, and enables the Company to deploy and expand the reach of its existing technology asset for new potential growth and high margin business opportunities, with low startup costs. For additional information, see Note 1 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K").

v3.24.3

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of presentation The Company's condensed consolidated financial statements have been prepared in conformity with the generally accepted accounting principles in the United States ("GAAP") as well as in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and include the accounts of the Company and its wholly-owned subsidiaries. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, necessary for a fair presentation of its financial condition and its results of operations for the periods presented. All material intercompany balances and transactions have been eliminated in consolidating these financial statements. Investments over which we exercise significant influence, but do not control, are accounted for using the applicable accounting treatment based on the nature of the investment. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the 2023 Form 10-K. Use of estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and the accompanying notes. The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, reinsurance, premium deficiency reserve, stock-based compensation, recoveries from third parties for coordination of benefits, and final determination of medical cost adjustment pools. Reclassifications Certain amounts in the prior year's Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current year's presentation, primarily related to Surety bonds and deposits and Change in restricted cash related to surety bonds, deposits, and escrow accounts. Discontinued Operations The results of operations for the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Assets and liabilities related to the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented in the Condensed Consolidated Balance Sheets. Refer to Note 17 (Discontinued Operations) for additional information. Equity method of accounting and variable interest entities Investments in entities in which the Company does not have control but its ownership falls between 20.0% and 50.0%, or it has the ability to exercise significant influence over operating and financial policies, are accounted for under the equity method of accounting. The Company continuously assesses its partially-owned entities to determine if these entities are variable interest entities ("VIEs") and, if so, whether the Company is the primary beneficiary and, therefore, required to consolidate the VIE. To make this determination, the Company applies a qualitative approach to determine whether the Company has both the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. If the Company has an interest in a VIE but is determined to not be the primary beneficiary, the Company accounts for the interest under the equity method of accounting. When the Company's carrying value in an equity method investee company is reduced to zero, no further losses are recorded in the Company's condensed consolidated financial statements unless the Company guaranteed obligations of the investee company or has committed additional funding. When the investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized. Segment information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. At September 30, 2024, the Company has one reportable segment, Insurance. Beginning in 2024, the Company exited the ACO REACH Model and as a direct result, the reportable operating segment formerly known as Non-Insurance no longer meets the criteria of a required reportable operating segment. Capitalized software development costs - cloud computing arrangements The Company's cloud computing arrangements are mostly comprised of hosting arrangements that are mostly service contracts, whereby the Company gains remote access to use enterprise software hosted by the vendor or another third party on an as-needed basis for a period of time in exchange for a subscription fee. Implementation costs for cloud computing arrangements are capitalized if certain criteria are met and consist of internal and external costs directly attributable to developing and configuring cloud computing software for its intended use. These capitalized implementation costs are presented in the Condensed Consolidated Balance Sheets within Prepaid expenses and are generally amortized over the fixed, non-cancelable term of the associated hosting arrangement on a straight-line basis. Deferred acquisition costs Acquisition costs directly related to the successful acquisition of new business, which are primarily made up of commissions costs, are deferred and subsequently amortized. Deferred acquisition costs are recorded within Other assets, current in the Condensed Consolidated Balance Sheets and are amortized over the estimated life of the related contracts. The amortization of deferred acquisition costs is recorded within General and administrative expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. For the three months ended September 30, 2024 and 2023, charges related to deferred acquisition costs of $2.7 million and $0.6 million, respectively. For the nine months ended September 30, 2024 and 2023, charges related to deferred acquisition costs of $5.5 million and $5.8 million, respectively, were recognized in General and administrative expenses. Restructuring Activities Restructuring related expenses, which are recorded within Restructuring costs in the Condensed Consolidated Statements of Operations and Comprehensive Loss, include employee termination benefits, vendor costs associated with restructuring activities, and other costs associated with the business transformation initiatives. Restructuring costs are determined based on estimates, which are prepared at the time the restructuring actions are approved by management and are periodically reviewed and updated for changes in estimates. The Company applies the provisions of ASC 420, Exit or Disposal Cost Obligations ("ASC 420") as these costs meet the criteria of a one-time benefit. Under ASC 420-10, the Company establishes a liability for a cost associated with an exit or disposal activity, including employee termination benefits and other restructuring related costs, when the liability is incurred, rather than at the date that the Company commits to an exit plan. At each reporting date, there is an evaluation of the liability to ensure the amount is still appropriate. See Note 16 (Restructuring costs) for further discussion. Recent accounting pronouncements Recently adopted accounting pronouncements There have been no new accounting pronouncements adopted during the nine months ended September 30, 2024 that had a material impact on the Company's condensed consolidated financial statements. Accounting pronouncements effective in future periods In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement—Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation—Stock Compensation (Topic 718); Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280—General Revision of Regulation S-X: Income or Loss Applicable to Common Stock (“ASU 2023-03”). This ASU amends or supersedes various SEC paragraphs within the applicable codification to conform to past SEC staff announcements. This ASU does not provide any new guidance. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on its condensed consolidated financial statements and related disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update aim to improve reportable segment disclosures by requiring enhanced disclosures around significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual disclosures about segment profit or loss must be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years beginning after December 15, 2024. A public entity should apply ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update aim to provide more transparency regarding tax disclosures mainly related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its condensed consolidated financial statements and related disclosures.

v3.24.3

Investment Securities	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investment Securities	Investment Securities The following tables present amortized cost and fair values of investments at September 30, 2024 and December 31, 2023, respectively: September 30, 2024 Amortized cost Accumulated unrealized gains Accumulated unrealized losses Fair value (in thousands) Investment securities, held-to-maturity U.S. government and government agencies and authorities $ 14,309  $ 7  $ (123) $ 14,193  Investment securities, available-for-sale U.S. government and government agencies and authorities 141,551  1,396  (1,258) 141,689  Corporate debt securities 83,321  714  (32) 84,003  Other 1,663  32  —  1,695  Total held-to-maturity and available-for-sale investment securities $ 240,844  $ 2,149  $ (1,413) $ 241,580  December 31, 2023 Amortized cost Accumulated unrealized gains Accumulated unrealized losses Fair value (in thousands) Investment securities, held-to-maturity U.S. government and government agencies and authorities $ 7,695  $ —  $ (225) $ 7,470  Investment securities, available-for-sale U.S. government and government agencies and authorities 126,071  713  (3,070) 123,714  Corporate debt securities 95,354  165  (176) 95,343  Other 1,855  —  (2) 1,853  Total held-to-maturity and available-for-sale investment securities $ 230,975  $ 878  $ (3,473) $ 228,380  The following table presents the amortized cost and fair value of debt securities at September 30, 2024, by contractual maturity: September 30, 2024 Held-to-maturity Available-for-sale Amortized cost Fair value Amortized cost Fair value (in thousands) Due within one year $ 15  $ 15  $ 43,695  $ 43,302  Due after one year through five years 14,183  14,083  182,840  184,085  Due after five years through ten years —  —  —  —  Due after ten years 111  95  —  —  Total $ 14,309  $ 14,193  $ 226,535  $ 227,387  For the three and nine months ended September 30, 2024 and 2023, respectively, net investment income, which is included in Other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, was derived from the following sources: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Cash and cash equivalents $ 4,488  $ 1,944  $ 10,120  $ 5,978  Short-term investments 232  605  548  1,920  Investment securities 2,099  1,840  6,351  5,322  Investment income, net $ 6,819  $ 4,389  $ 17,019  $ 13,220  Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at September 30, 2024, and December 31, 2023, respectively: September 30, 2024 Less than 12 months Greater than 12 months Total Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss (in thousands, except number of positions) U.S. government and government agencies and authorities $ 10,269  $ (40) $ 39,379  $ (1,341) $ 49,648  $ (1,381) Corporate debt securities 19,118  (30) 4,290  (2) 23,408  (32) Total $ 29,387  $ (70) $ 43,669  $ (1,343) $ 73,056  $ (1,413) Number of positions 21  19  40  December 31, 2023 Less than 12 months Greater than 12 months Total Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss (in thousands, except number of positions) U.S. government and government agencies and authorities $ 12,584  $ (32) $ 61,628  $ (3,259) $ 74,212  $ (3,291) Corporate debt securities 61,007  (175) 5,017  (7) 66,024  (182) Total $ 73,591  $ (207) $ 66,645  $ (3,266) $ 140,236  $ (3,473) Number of positions 69  27  96  The Company did not record any credit allowances for debt securities that were in an unrealized loss position at September 30, 2024 and December 31, 2023. At September 30, 2024, all securities were investment grade, with credit ratings of BBB+ or higher by S&P Global or as determined by other credit rating agencies within the Company's investment policy. Unrealized losses on investment grade securities are principally related to changes in interest rates or changes in issuer or sector related credit spreads since the securities were acquired. The gross unrealized investment losses at September 30, 2024, were assessed, based on, among other things: •The relative magnitude to which fair values of these securities have been below their amortized cost was not indicative of an impairment loss; •The absence of compelling evidence that would cause the Company to call into question the financial condition or near-term prospects of the issuer of the applicable security; and •The Company's ability and intent to hold the applicable security for a period of time sufficient to allow for any anticipated recovery. Proceeds from sales and maturities of investment securities, inclusive of short-term investments, and related gross realized gains (losses) which are included in Other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, were as follows for the three and nine months ended September 30, 2024 and 2023, respectively: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Proceeds from sales of investment securities $ 47,804  $ —  $ 47,804  $ 60,436  Proceeds from maturities of investment securities 42,137  32,240  108,788  139,122  Gross realized gains 170  —  174  39  Gross realized losses —  —  —  (19) Net realized gains $ 170  $ —  $ 174  $ 20  At September 30, 2024 and December 31, 2023, the Company had $14.9 million and $14.7 million, respectively, in deposits with various states and regulatory bodies that are included as part of the Company's investment balances.

v3.24.3

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present a summary of fair value measurements for financial instruments at September 30, 2024 and December 31, 2023, respectively: September 30, 2024 Level 1 Level 2 Level 3 Total fair value (in thousands) U.S. government and government agencies $ —  $ 141,689  $ —  $ 141,689  Corporate debt securities —  84,003  —  84,003  Other —  1,695  —  1,695  Warrants receivable —  —  797  797  Total assets at fair value $ —  $ 227,387  $ 797  $ 228,184  December 31, 2023 Level 1 Level 2 Level 3 Total fair value (in thousands) U.S. government and government agencies $ —  $ 123,714  $ —  $ 123,714  Corporate debt securities —  95,343  —  95,343  Other 1,853  —  —  1,853  Warrants receivable —  —  814  814  Total assets at fair value $ 1,853  $ 219,057  $ 814  $ 221,724  The changes in balances of Clover's Level 3 financial assets and liabilities during the nine months ended September 30, 2024 were as follows: Warrants receivable Total (in thousands) Balance, December 31, 2023 $ 814  $ 814  Total unrealized losses 17  17  Balance, September 30, 2024 $ 797  $ 797  There were no transfers in or out of Level 3 financial assets or liabilities for the nine months ended September 30, 2024 or September 30, 2023. Private Warrants At September 30, 2024, the Company had exercisable private warrants which were embedded in several agreements as derivatives. These private warrants were accounted for as assets in accordance with ASC 815-40 and are presented in Other assets, non-current in the Condensed Consolidated Balance Sheets. The warrant assets are measured at fair value at inception and on a recurring basis until redeemed, with changes in fair value presented in Change in fair value of warrants in the Condensed Consolidated Statements of Operations and Comprehensive Loss. These private warrants were classified within Level 3 due to the subjectivity and use of estimates in the calculation of their fair value. These warrants at measurement date, December 31, 2023, were assessed to have a fair value of $0.8 million, with no other activity for the three months ended September 30, 2024. The Company reassesses the fair values of the warrants based on updated estimates and for the nine months ended September 30, 2024, there was less than $0.1 million unrealized losses recognized.

v3.24.3

Healthcare Receivables	9 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Healthcare Receivables	Healthcare Receivables Healthcare receivables include pharmaceutical rebates that are accrued as they are earned and estimated based on contracted rebate rates, eligible amounts submitted to the manufacturers by the Company's pharmacy manager, pharmacy utilization volume, and historical collection patterns. Also included in Healthcare receivables are Medicare Part D settlement receivables, member premium receivables, and other CMS receivables. The Company reported $37.3 million and $64.2 million within Healthcare receivables at September 30, 2024, and December 31, 2023, respectively.

v3.24.3

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party agreements The Company has various contracts with IJKG Opco LLC (d/b/a CarePoint Health - Bayonne Medical Center), Hudson Hospital Opco, LLC (d/b/a CarePoint Health - Christ Hospital) and Hoboken University Medical Center Opco LLC (d/b/a CarePoint Health - Hoboken University Medical Center), which collectively do business as the CarePoint Health System ("CarePoint Health"), for the provision of inpatient and hospital-based outpatient services. CarePoint Health was ultimately held and controlled by Vivek Garipalli, the Company's Executive Chairman and a significant stockholder of the Company. In May 2022, Mr. Garipalli and his family completed a donation of their interest in CarePoint Health to a non-profit organization called CarePoint Health Systems, Inc ("the CarePoint Nonprofit"). In September 2024, Sequoia Healthcare Services, LLC, an entity that Mr. Garipalli has an indirect interest in, transferred certain subsidiaries that provided services to CarePoint Health to the CarePoint Nonprofit. Following such transfer, neither Mr. Garipalli nor any entity he has an interest in currently provide any management services to CarePoint Health. However, Mr. Garipalli and certain affiliates of Mr. Garipalli are owed certain money from CarePoint Health for prior obligations. Expenses and fees incurred related to Clover's contracts with CarePoint Health, recorded in Net medical claims incurred, in the Condensed Consolidated Statements of Operations and Comprehensive Loss, were $2.5 million and $3.2 million for the three months ended September 30, 2024 and 2023, respectively, and $5.3 million and $9.7 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, $1.3 million and $1.4 million were payable to CarePoint Health at September 30, 2024, and December 31, 2023, respectively. The Company has a contract with Medical Records Exchange, LLC (formerly known as "ChartFast," now d/b/a Credo) pursuant to which the Company receives administrative services related to medical records retrieval via Credo's electronic applications and web portal platform. Expenses and fees incurred related to this agreement were $0.1 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively, and $0.5 million and $0.6 million for the nine months ended September 30, 2024 and 2023, respectively. Vivek Garipalli, the Company's Executive Chairman and significant stockholder of the Company, is an indirect owner of Medical Records Exchange, LLC. Since July 2, 2021, the Company has contracted with Thyme Care, Inc. ("Thyme Care"), an oncology care management company, through which Thyme Care was engaged to provide cancer care management services to the Company's Insurance members and develop a provider network to help ensure member access to high-value oncology care. The Company and Thyme Care have amended the terms of the engagement, effective April 1, 2023, to include additional clinical services available to Clover members as well as the value based payment terms. The Company entered into an agreement with Thyme Care effective September 23, 2020 where the Company purchased 1,773,049 shares (less than five percent (5%) of its class A common stock). The fair value of these shares is $1.8 million at September 30, 2024, and is recognized in Other assets, non-current, in the Condensed Consolidated Balance Sheets. In accordance with ASC 321, any changes in fair value associated with these shares are recognized in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Mr. Garipalli is a member of the board of directors of Thyme Care and holds an equity interest of less than five percent (5%) of that entity. Expenses and fees incurred related to this agreement were $0.9 million and $0.9 million for the three months ended September 30, 2024 and 2023, respectively, and $3.2 million and $1.7 million for the nine months ended September 30, 2024 and 2023, respectively. Additionally, $3.0 million and $0.2 million were payable to Thyme Care at September 30, 2024, and December 31, 2023, respectively.

v3.24.3

Unpaid Claims	9 Months Ended
	Sep. 30, 2024
Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]
Unpaid Claims	Unpaid Claims Activity within the liability for Unpaid claims, including claims adjustment expenses, for the nine months ended September 30, 2024 and 2023, respectively, is summarized as follows: Nine Months Ended September 30, 2024 2023 (in thousands) Gross and net balance, beginning of period (1) $ 137,100  $ 137,395  Incurred related to: Current year 780,461  750,705  Prior years (31,523) (7,689) Total incurred 748,938  743,016  Paid related to: Current year 622,126  646,322  Prior years 96,502  120,859  Total paid 718,628  767,181  Gross and net balance, end of period (1) $ 167,410  $ 113,230  (1)    Includes amounts due to related parties. The Company uses a variety of standard actuarial techniques to establish unpaid claims reserves. Management estimates are supported by the Company's actuarial analysis. The Company utilizes an internal actuarial team to review the adequacy of unpaid claim and unpaid claim adjustment expense. The estimation of claim costs is inherently difficult and requires significant judgment. The estimation has considerable inherent variability and can fluctuate significantly depending upon several factors, including medical cost trends and claim payment patterns, general economic conditions, and regulatory changes. The time value of money is not taken into account for the purposes of calculating the liability for unpaid claims. Management believes that the current reserves are adequate based on currently available information. Unpaid Claims for Insurance Operations Unpaid claims for Insurance operations were $167.4 million at September 30, 2024. During the nine months ended September 30, 2024, $96.5 million was paid for incurred claims attributable to insured events of prior years. A favorable development of $31.5 million was recognized during the nine months ended September 30, 2024, resulting from the Company's actual experience with claims developing differently as compared to the Company's estimates at December 31, 2023. A favorable development of $7.7 million was recognized during the nine months ended September 30, 2023, resulting from the Company's actual experience with claims developing differently as compared to the Company's estimates at December 31, 2022. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. The ratio of current year medical claims paid as a percentage of current year Net medical claims incurred was 79.7% for the nine months ended September 30, 2024, and 86.1% for the nine months ended September 30, 2023. This ratio serves as an indicator of claims processing speed, indicating that claims were processed at a slower rate during the nine months ended September 30, 2024, than during the nine months ended September 30, 2023. As a result of slower claims processing, unpaid claims liability increased which was primarily due to claim submission and payment process disruptions related to a third-party cyber incident.

v3.24.3

Stockholders' Equity and Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2024
Equity And Temporary Equity [Abstract]
Stockholders' Equity and Convertible Preferred Stock	Stockholders' Equity and Convertible Preferred Stock Stockholders' Equity The Company was authorized to issue up to 2,500,000,000 shares of Class A common stock at September 30, 2024 and December 31, 2023, respectively, and up to 500,000,000 shares of Class B common stock at September 30, 2024 and December 31, 2023. At September 30, 2024 and December 31, 2023, there were 411,256,965 and 401,183,882 shares of Class A common stock issued and outstanding, respectively. There were 89,032,305 and 87,867,732 shares of Class B common stock issued and outstanding at September 30, 2024 and December 31, 2023, respectively. Class B common stock has 10 votes per share, and Class A common stock has one vote per share. The Company had 16,817,010 and 7,912,750 shares held in treasury at September 30, 2024 and December 31, 2023, respectively. These amounts represent shares withheld to cover taxes upon vesting of employee stock-based awards. On May 6, 2024, the Board of Directors of the Company authorized the repurchase of up to $20,000,000 in shares of the Company’s outstanding Class A Common Stock over a two year period. The timing, manner, price and amount of any repurchases are determined by the discretion of management, depending on market conditions and other factors. Repurchases may be made through open market purchases, including through Rule 10b5-1 trading plans, block trades or privately negotiated purchases or otherwise. The exact number of shares to be repurchased by the Company, if any, is not guaranteed, and there is no minimum number of shares that the Company is required to purchase. Depending on market conditions and other factors, these repurchases may be commenced, suspended or discontinued at any time or periodically without prior notice. Shares repurchased by the Company are accounted for on the settlement date. Upon settlement, repurchased shares are held as treasury shares and are no longer considered outstanding. The total cost to repurchase shares includes any direct costs incurred, including broker commissions and excise taxes, and is recorded as a reduction to additional paid in capital in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2024, the Company repurchased 1,838,309 shares for an aggregate total of $1.8 million. At September 30, 2024, the Company was authorized to issue 25,000,000 shares of preferred stock having a par value of $0.0001 per share, and the Company's Board has the authority to determine the rights, preferences, privileges, and restrictions, including voting rights, of those shares. At September 30, 2024, there were no shares of preferred stock issued and outstanding.

v3.24.3

Variable Interest Entity and Equity Method of Accounting	9 Months Ended
	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Variable Interest Entity and Equity Method of Accounting	Variable Interest Entity and Equity Method of Accounting On February 4, 2022, Character Biosciences, Inc. (f/k/a Clover Therapeutics Company) ("Character Biosciences"), an affiliate of the Company, completed a private capital transaction in which it raised $17.9 million from the issuance of 16,210,602 shares of its preferred stock. Upon completion of the transaction, the Company owned approximately 25.46% of Character Biosciences. As a result, the Company reassessed its interest in Character Biosciences and determined that while Character Biosciences is a VIE, the Company is not considered the primary beneficiary of the VIE because it does not have the power, through voting or similar rights and the license agreements, to direct the activities of Character Biosciences that most significantly impact Character Biosciences' economic performance. On January 23, 2023, Character Biosciences, completed a second private capital transaction in which it raised additional capital from the issuance of additional shares of its preferred stock. Upon completion of this transaction, the Company's ownership percentage in Character Biosciences decreased to 23.92%. The Company determined that it does have a significant influence over Character Biosciences and, therefore, it began accounting for its common stock investment in Character Biosciences using the equity method on February 4, 2022. As the Company applies the equity method to account for its common stock interest in Character Biosciences, the initial value of the investment is adjusted periodically to recognize (i) the proportionate share of the investee's net income or losses after the date of investment, (ii) additional contributions made and dividends or distributions received, and (iii) impairment losses resulting from adjustments to net realizable value. The Company eliminates all intercompany transactions in accounting for equity method investments and records the proportionate share of the investee's net income or loss in equity in loss on investment in the Consolidated Statements of Operations and Comprehensive Loss. In accordance with ASC 323, Investments - Equity Method and Joint Ventures (“ASC 323”), the Company recognized the proportionate share of Character Bioscience's net loss up to the investment carrying amount. As a result, the Company did not recognize any shared gain or loss for the three months ended September 30, 2024 and 2023, respectively, and recognized a loss of $0.5 million and none for the nine months ended September 30, 2024 and 2023, respectively. The equity method investment in Character Biosciences was reduced to zero during the three months ended March 31, 2024 and no further losses can recorded in the Company's condensed consolidated financial statements as the Company did not guarantee obligations of the investee company nor has not committed additional funding. The Company will begin recognizing its share of net income only when it is greater than the cumulative net losses not recognized during the period the equity method was suspended.

v3.24.3

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Employee Benefit Plans	Employee Benefit Plans Employee Savings Plan The Company has a defined contribution retirement savings plan (the "401(k) Plan") covering eligible employees, which includes safe harbor matching contributions based on the amount of employees' contributions to the 401(k) Plan. The Company contributes to the 401(k) Plan annually 100.0% of the first 4.0% compensation that is contributed by the employee up to 4.0% of eligible annual compensation after one year of service. The Company's service contributions to the 401(k) Plan amounted to approximately $0.5 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively, and $1.6 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively, and are included in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company's cash match is invested pursuant to the participant's contribution direction. Employer contributions are immediately 100.0% vested. Stock-based Compensation The Company's 2020 Equity Incentive Plan (the "2020 Plan") provides for grants of restricted stocks units ("RSUs"), performance-based restricted stock units ("PRSUs") and stock options to acquire shares of the Company's common stock, to employees, directors, officers, and non-employee consultants of the Company and its affiliates, and the Company's 2020 Management Incentive Plan (the "2020 MIP") provides for grants of RSUs and PRSUs to the Company's Executive Chair and CEO. During the year ended December 31, 2021, the Company approved the 2020 Plan and the 2020 MIP, and the Company's 2014 Equity Incentive Plan (the "2014 Plan") was terminated. When the 2014 Plan was terminated, the outstanding awards previously granted thereunder were assumed by the Company, and no new awards are available for grant under the 2014 Plan. Shares that are expired, terminated, surrendered, or canceled under the 2014 Plan without having been fully exercised are available for awards under the 2020 Plan. On March 9, 2022, the Board adopted the Company's 2022 Inducement Award Plan (the "Inducement Plan" and, collectively with the 2020 Plan, the 2020 MIP, and the 2014 Plan, the "Plans") without stockholder approval in accordance with Nasdaq Listing Rules. Under the Inducement Plan, the Company may grant non-qualified stock options, RSUs, stock appreciation rights, and other stock or cash-based awards to an employee in connection with his or her commencement of employment, or following a bona fide period of non-employment, with the Company or an affiliate. The 2020 Plan has an evergreen provision that requires the number of shares available for issuance under the plan to be increased on the first day of each fiscal year beginning with the 2022 fiscal year and ending on (and including) the last day of the 2024 fiscal year, in each case, in an amount equal to the lesser of (i) seven percent (7%) of the outstanding shares of Class A common Stock on the last day of the immediately preceding fiscal year and (ii) such number of shares of Class A common Stock determined by the Board; provided that for each fiscal year beginning with the 2025 fiscal year through the fiscal year that includes the expiration date of the plan, each such increase shall be reduced to the lesser of five percent (5%) of the outstanding shares of Class A common Stock on the last day of the immediately preceding fiscal year or such number of shares as determined by the Board. The maximum number of shares of the Company's common stock reserved for issuance over the term of the Plans, shares outstanding under the Plans, and shares remaining under the Plans at September 30, 2024 were as follows: September 30, 2024 Shares Authorized Under Plans Shares Outstanding Under Plans Shares Remaining Under Plans 2014 Plan 54,402,264  34,457,710  N/A 2020 Plan 86,604,581  39,844,072  19,817,658  2020 MIP 33,426,983  23,398,889  —  Inducement Plan 11,000,000  6,293,605  —  The Plans are administered by the Talent and Compensation Committee of the Board (the "Compensation Committee"). Stock options granted under the Plans are subject to the terms and conditions described in the applicable Plan and the applicable stock option grant agreement. The exercise prices, vesting, and other restrictions applicable to the stock options are determined at the discretion of the Compensation Committee, except that the exercise price per share of incentive stock options may not be less than 100.0% of the fair market value of a share of common stock on the date of grant. Stock options awarded under the Plans expire 10 years after the grant date and generally vest over four or five years. The number of stock options granted is determined by dividing the approved grant date dollar value of an option by the Black Scholes option pricing value per share (as further discussed below). RSU awards are subject to the terms and conditions set forth in the Plans and the applicable RSU grant agreement. Vesting and other restrictions applicable to RSU awards are determined at the discretion of the Compensation Committee, but generally vest over one to four years from the date of the grant. The number of RSUs granted is determined by dividing the cash value of an RSU award by the average closing price of a share of the Company's Class A common stock over a specified period through the date of grant. The total estimated grant date fair value is amortized over the requisite service period. The Company recorded Stock-based compensation for stock options, RSUs, and PRSUs granted under the Plans, and discounts offered in connection with the Company's 2020 Employee Stock Purchase Plan ("ESPP") of $28.0 million and $33.1 million during the three months ended September 30, 2024 and 2023, respectively, and $84.7 million and $107.8 million during the nine months ended September 30, 2024 and 2023, respectively, and such expenses are presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Compensation cost presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss were as follows: Three Months Ended September 30, 2024 2023 (in thousands) Stock options $ 384  $ 559  RSUs 21,074  20,603  PRSUs 6,170  11,851  ESPP 360  57  Total compensation cost recognized for stock-based compensation plans $ 27,988  $ 33,070  Nine Months Ended September 30, 2024 2023 (in thousands) Stock options $ 1,532  $ 2,648  RSUs 62,391  62,539  PRSUs 20,327  42,444  ESPP 436  164  Total compensation cost recognized for stock-based compensation plans $ 84,686  $ 107,795  At September 30, 2024, there was approximately $383.4 million of unrecognized stock-based compensation expense related to unvested stock options, unvested RSUs and unvested PRSUs, estimated to be recognized over a period of four years. Stock Options The Company did not grant stock options during the nine months ended September 30, 2024 and 2023, respectively. A summary of option activity under the 2020 Plan during the nine months ended September 30, 2024, was as follows: Number of stock options Weighted-average exercise price Outstanding, January 1, 2024 952,900  $ 8.88  Granted —  —  Exercised —  —  Forfeited (131,212) 8.88  Outstanding, September 30, 2024 821,688  $ 8.88  A summary of stock option activity under the 2014 Plan during the nine months ended September 30, 2024, was as follows: Number of stock options Weighted-average exercise price Outstanding, January 1, 2024 24,041,753  $ 1.45  Granted —  —  Exercised (210,555) 1.16  Forfeited (120,650) 3.44  Outstanding, September 30, 2024 23,710,548  $ 2.73  At September 30, 2024, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $16.2 million, and a weighted-average remaining contractual term of four years. At September 30, 2024, there were 24,160,751 options exercisable under the Plan, with an aggregate intrinsic value of less than $16.2 million, a weighted-average exercise price of $2.88 per share, and a weighted-average remaining contractual term of 4.68 years. The total value of stock options exercised during the nine months ended September 30, 2024 and 2023 was $0.3 million. Cash received from stock option exercises during the nine months ended September 30, 2024 and 2023 totaled $0.2 million and none, respectively. Restricted Stock Units A summary of total RSU activity is presented below: Number of RSUs Weighted-average grant date fair value per share Outstanding, January 1, 2024 56,928,405  $ 4.28  Granted 17,639,741  0.97  Released (17,249,172) 4.56  Forfeited (7,625,408) 1.93  Outstanding, September 30, 2024 49,693,566  $ 3.37  Performance Restricted Stock Units The Company has granted PRSUs to certain executives and key employees, which become eligible to vest based on achievement of certain Company or individual performance milestones (“Non-Market PRSUs”) and certain Company stock price targets (“Market PRSUs”), each as determined by the Compensation Committee. Market PRSUs will vest if prior to the vesting date the average closing price of one share of the Company's common stock for 90 consecutive days equals or exceeds a specified price. The expense referenced above is mainly attributable to Market PRSUs that vest based on pre-established milestones that primarily consist of the volume-weighted average stock closing price ranging from $20 to $30 for 90 consecutive days. The grant date fair value of the Non-Market PRSUs was based on the closing price of the Company’s Class A common stock and recognized as expense over the requisite performance period under the accelerated attribution method and is adjusted in future periods for the success or failure to achieve the specified performance condition. The grant date fair value of the Market PRSUs was determined using a Monte Carlo simulation model that incorporated multiple valuation assumptions, including the probability of achieving the specified market condition. Expense for Market PRSUs is recognized over the derived service period under the accelerated attribution method and is not adjusted in future periods for the success or failure to achieve the specified market condition. The assumptions that the Company used in the Monte Carlo model to determine the grant date fair value of Market PRSUs granted for the year ended December 31, 2021, were as follows: Year ended December 31, 2021 Expected volatility (1) 40.7  % Risk-free interest rate (2) 0.5  Dividend yield (3) —  (1) Expected volatility is based on a blend of peer group company historical data adjusted for the Company's leverage. (2) Risk-free interest rate based on U.S. Treasury yields with a term equal to the remaining Performance Period as of the grant date. (3) Dividend yield was assumed to be zero as the Company does not anticipate paying dividends. At September 30, 2024, the market condition component of these PRSUs has not been met, so the awards have not been earned. This expense represents most of the PRSU expense recognized for the three and nine months ended September 30, 2024 related to stock-based compensation plans which is presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has also determined the requisite service period for the PRSUs with multiple performance conditions to be the longest of the explicit, implicit, or derived service period for each tranche. A summary of PRSU activity is presented below: Number of PRSUs Weighted-average grant date fair value per share Non-vested, January 1, 2024 32,131,532  $ 8.36  Granted during 2024 —  —  Adjustment for performance condition achieved(1) 341,459  0.95  Vested (2,389,515) 1.14  Forfeited (315,292) 1.56  Non-vested at September 30, 2024 29,768,184  $ 8.93  (1) Represents an increase in the number of original CLOV performance share units awarded based on final achievement at the end of the performance period of such awards. At September 30, 2024, there was $18.2 million of unrecognized share-based compensation expense related to PRSUs, which is expected to be recognized over a period of four years. 2020 Employee Stock Purchase Plan On January 6, 2021, the Board adopted and the Company's stockholders approved the ESPP, which permits eligible employees and service providers of either the Company or designated related companies and affiliates to contribute up to 15% of their eligible compensation during defined offering periods to purchase shares of the Company’s Class A common stock at a 15% discount from the fair market value of the common stock as determined on specific dates at specific intervals. Subject to adjustments provided in the ESPP that are discussed below, the maximum number of shares of common stock that may be purchased under the ESPP is 14,163,863 shares, and the maximum number of shares that may be purchased on any single purchase date by any one participant is 5,000 shares. At September 30, 2024, 12,851,030 shares of Class A common stock were available for issuance under the ESPP. The ESPP includes an evergreen provision that limits the maximum number of shares of Class A common stock that may be issued under the plan, to 2,785,582 shares, plus the number of shares of Class A common stock that are automatically added on the first day of each fiscal year beginning with the 2022 fiscal year and ending on (and including) the first day of the 2030 fiscal year, in an amount equal to the lesser of (i) one percent (1%) of the total number of shares of Class A common stock outstanding on the last day of the calendar month prior to the date of such automatic increase, and (ii) such number of shares of Class A common stock as determined by the Board; provided that the maximum number of shares of Class A common stock reserved under the ESPP shall not exceed 10.0% of the total outstanding capital stock of the Company (inclusive of the shares reserved under the ESPP) as of January 7, 2021, on an as-converted basis. The assumptions that the Company used in the Black-Scholes option-pricing model to determine the fair value of the purchase rights under the ESPP for the most recent offering period, is as follows: Offering period from May 22, 2024 to November 21, 2024 Weighted-average risk-free interest rate 5.4  % Expected term (in years) 0.50 Expected volatility 64.0  %

v3.24.3

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The consolidated effective tax rate of the Company for the three and nine months ended September 30, 2024 and 2023, was 0.0%, and 0.0% respectively. The Company continues to be in a net operating loss for the nine months ended September 30, 2024 and net deferred tax asset position. As a result, and in accordance with accounting standards, the Company recorded a valuation allowance to reduce the value of the net deferred tax assets to zero. The Company believes that at September 30, 2024, it had no material uncertain tax positions. Interest and penalties related to unrecognized tax expense (benefits) are recognized in income tax expense, when applicable. There were no material liabilities for interest and penalties accrued at September 30, 2024 and December 31, 2023.

v3.24.3

Net Income (Loss) per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Income (Loss) per Share	Net Income (Loss) per Share Basic and diluted net loss per share from continuing operations attributable to Class A common stockholders and Class B common stockholders (collectively, "Common Stockholders") for the years indicated were calculated as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands, except for per share and share amounts) Numerator: Net loss from continuing operations attributable to Common Stockholders $ (8,785) $ (33,616) $ (24,785) $ (142,203) Net (loss) income from discontinued operations attributable to Common Stockholders (370) (7,853) 3,868  (686) Denominator: Basic weighted average number of common shares and common share equivalents outstanding 490,180,103  480,770,283  488,501,812  480,921,520  Dilutive shares: RSU N/A N/A N/A N/A PRSU N/A N/A N/A N/A Stock Options N/A N/A N/A N/A Weighted average shares used in computing net income per share of common stock, diluted 490,180,103  480,770,283  488,501,812  480,921,520  Basic loss per share from continuing operations $ (0.02) $ (0.07) $ (0.05) $ (0.30) Basic earnings (loss) per share from discontinued operations 0.00 (0.02) 0.01 0.00 Diluted loss per share from continuing operations (0.02) (0.07) (0.05) (0.30) Diluted earnings (loss) per share from discontinued operations 0.00 (0.02) 0.01 0.00 For all periods presented, the Company had net loss from continuing operations attributable to Common Stockholders. As a result, the Company's potentially dilutive securities, which include Options, RSUs, and PRSUs, have been excluded from the computation of diluted net loss per share from continuing operations, as the effect would be anti-dilutive. Therefore, during these periods, the diluted common shares outstanding equals the average common shares outstanding. The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income (loss) per share of common stock: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Options to purchase common stock 24,532,236  25,138,347  24,532,236  25,138,347  RSUs 49,693,566  55,544,997  49,693,566  55,544,997  PRSUs 29,768,184  30,224,866  29,768,184  30,224,866  Total potentially dilutive shares excluded from computation of net income (loss) per share 103,993,986  110,908,210  103,993,986  110,908,210

v3.24.3

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Actions Various lawsuits against the Company may arise in the ordinary course of the Company's business. Contingent liabilities arising from ordinary course litigation, income taxes and other matters are not expected to be material in relation to the financial position of the Company. At September 30, 2024, and December 31, 2023, respectively, there were no material known contingent liabilities arising outside the normal course of business other than as set forth below. In accordance with ASC No. 450-20, Loss Contingencies, we will record accruals for loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Securities Class Actions, Derivative Litigation and Investigations Since February 2021, the Company has received subpoenas from the SEC related to certain disclosures and aspects of our business as well as certain matters described in an article issued on February 4, 2021, by Hindenburg Research LLC (the "Hindenburg Article"). The Company is cooperating with the SEC's investigation (the "Investigation"). The Hindenburg Article, which discussed, among other things, an inquiry by the U.S. Attorney's Office for the Eastern District of Pennsylvania relating to, among other things, certain of the Company’s arrangements with providers participating in its network and programs, and Clover Assistant, was the subject of the Company’s Current Report on Form 8-K dated February 5, 2021. As previously disclosed on the Company's Current Report on Form 8-K filed on September 30, 2024, by letter dated September 26, 2024 (the “Notice”), the Staff of the SEC Division of Enforcement notified the Company that the SEC had concluded the Investigation, and based on the information that the SEC had as of the date of the Notice, the Staff did not intend to recommend an enforcement action by the SEC against the Company relating to the Investigation. In February 2021, the Company and certain of its directors and officers were named as defendants in putative class actions filed in the United States District Court for the Middle District of Tennessee: Bond v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00096 (M.D. Tenn.); Kaul v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00101 (M.D. Tenn.); Yaniv v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00109 (M.D. Tenn.); and Tremblay v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00138 (M.D. Tenn.). The complaints assert violations of sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act. The Kaul action asserts additional claims under sections 11 and 15 of the Securities Act. The complaints generally relate to allegations published in the Hindenburg Article. The complaints seek unspecified damages on behalf of all persons and entities who purchased or acquired Clover securities during the class period (which begins on October 6, 2020, and, depending on the complaint, ends on February 3, 2021, or February 4, 2021), as well as certain other costs. In April 2021, the Middle District of Tennessee class actions were consolidated under Bond v. Clover Health Investments, Corp. et al., Case No. 3:21-cv-00096 (M.D. Tenn.) as the lead case. On June 28, 2021, the plaintiffs filed an amended complaint, which also generally relates to allegations published in the Hindenburg Article, but adds, among other things, allegations from confidential witnesses who purport to be former employees of the Company. The Company moved to dismiss the amended complaint on August 28, 2021; that motion was denied on February 28, 2022. On February 14, 2023, the court granted the plaintiffs' motion for class certification. On April 21, 2023, the parties to the securities class action entered into a memorandum of understanding providing for the settlement of the action. The Court approved the settlement and dismissed the action with prejudice on October 3, 2023. Under the settlement, the class will receive $22 million dollars (less an award of fees and expenses to the plaintiffs’ counsel), and the defendants (including the Company) received customary releases. The Company used $19.5 million in insurance proceeds to fund the settlement. The Company previously filed a lawsuit in Delaware state court against certain of its insurers for full payment of its liabilities related to this securities litigation. The Company intends to oppose any efforts by the carrier defendants to recoup insurance proceeds that they have advanced to date. Shareholder derivative actions parallel to the securities class action have also been filed, naming Clover as a nominal defendant. The first action was filed in the United States District Court for the District of Delaware and is captioned Furman v. Garipalli, et al., Case No. 1:21-cv-00191 (D. Del.). The complaint asserts violations of sections 10(b) and 21D of the Exchange Act, breach of fiduciary duty, and waste of corporate assets against certain of the Company's directors. It seeks unspecified damages and an order requiring Clover to take certain actions to enhance Clover's corporate governance policies, and procedures. The second and third actions were filed in the United States District Court for the Middle District of Tennessee and are captioned Sun v. Garipalli, et al., Case No. 3:21-cv-00311 (M.D. Tenn.), and Luthra v. Garipalli, et al., Case No. 3:21-cv-00320 (M.D. Tenn.). The complaints assert violations of section 14(a) of the Exchange Act, breach of fiduciary duty, and aiding and abetting a breach of fiduciary duty. The Sun action also asserts unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution under section 11(f) of the Securities Act, and sections 10(b) and 21D of the Exchange Act. The complaints name certain current and former officers and directors as defendants. They seek unspecified damages and an order requiring Clover to take certain actions to enhance Clover's corporate governance policies and procedures. The fourth action was filed in the United States District of Delaware and is captioned Wiegand v. Garipalli, et al., Case No. 1:21-cv-01053 (D. Del.). The initial complaint asserted violations of sections 14(a) and 20(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste of corporate assets. The complaint names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages and an order requiring Clover to take certain actions to improve Clover's corporate governance and internal procedures. The fifth action was filed in the Supreme Court of the State of New York and is captioned Sankaranarayanan v. Palihapitiya, et al., Index No. 655420/2021 (N.Y. Sup. Ct., N.Y. Cnty.). The complaint asserts breach of fiduciary duty and unjust enrichment. The complaint names certain former officers and directors as defendants. It seeks, among other things, unspecified damages and an order directing Clover to take certain actions to reform and improve its corporate governance and internal procedures. The sixth action was filed in the Delaware Court of Chancery and is captioned Davies v. Garipalli, et al., No. 2021-1016-SG (Del. Ch.). The complaint asserts breach of fiduciary duty. The complaint names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages and an order directing Clover to take certain actions to reform and improve its corporate governance and internal procedures. The seventh action was filed in the Supreme Court of the State of New York and is captioned Uvaydov v. Palihapitiya, et al., Index No. 656978/2021 (N.Y Sup. Ct., N.Y. Cnty.). The complaint asserts breach of fiduciary duty, unjust enrichment, and aiding and abetting a breach of fiduciary duty. The complaint names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages, restitution, and disgorgement of profits obtained by defendants. On May 10, 2021, the Middle District of Tennessee shareholder derivative actions described above were consolidated under Sun v. Garipalli, et al., Case No. 3:21-cv-00311 (M.D. Tenn.) as lead case. On November 30, 2021, the Sun and Luthra plaintiffs filed an amended complaint, asserting violations of section 14(a) of the Exchange Act, breach of fiduciary duty, aiding and abetting a breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution under sections 10(b) and 21D of the Exchange Act. The amended complaint generally relates to the allegations published in the Hindenburg Article, and names certain current and former officers and directors as defendants. It seeks, among other things, unspecified damages and an order requiring Clover to take certain actions to enhance Clover's corporate governance policies and procedures. On September 16, 2021, the two District of Delaware derivative actions were consolidated under In re Clover Health Investments, Corp. Derivative Litigation, Case No. 1:21-cv-00191-LPS (Consolidated). The Furman complaint was deemed the operative complaint. On April 19, 2022, the plaintiff in the Wiegand action filed an amended complaint, asserting violations of Sections 10(b), 20(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment against certain current and former officers and directors. The amended complaint seeks, among other things, unspecified damages and an order requiring Clover to take certain actions to improve Clover's corporate governance and internal procedures. On August 19, 2022, the two derivative actions filed in New York state court were consolidated under In re Clover Health Investments, Corp. Stockholder Derivative Litig., Index No. 655420/2021. On November 3, 2022, the plaintiffs in this action filed a consolidated complaint, asserting breach of fiduciary duty, and unjust enrichment, and naming certain former officers and directors as defendants. The complaint seeks, among other things, unspecified damages, restitution, the disgorgement of profits obtained by defendants, and an order directing Clover to take certain actions to reform and improve its corporate governance and internal procedures. On June 21, 2023, the plaintiffs in the derivative lawsuits, on the one hand, and the Company, on the other hand, entered into a binding memorandum of understanding providing for the settlement of the derivative actions. On February 5, 2024, the parties executed a stipulation of settlement which, subject to final court approval, will provide the defendants in the derivative lawsuits with customary releases and will require the Company to implement a suite of corporate governance enhancements. On July 11, 2024, the United States District Court for the Middle District of Tennessee entered a final judgment approving the settlement. The settlement does not involve any monetary payment, other than payment of an award of fees and expenses to plaintiffs’ counsel in the amount of $2,500,000. Bylaw Litigation On March 26, 2024, a putative shareholder filed a class action suit against the Company and its directors and officers in Delaware Chancery Court challenging a Company bylaw governing the process for nominating a candidate to the board of directors as preclusive and coercive. The case is captioned Taylor v. Clinton, et al., Case No. 2024-0305 (Del. Ch.). In June 2024, the Company adopted an amendment to its bylaws mooting the litigation, and the plaintiffs voluntarily dismissed the suit, with the court retaining jurisdiction solely for the purpose of determining plaintiffs’ counsel’s application for attorneys’ fees and reimbursement (the “Fee Application”). On October 23, 2024, solely to avoid the time and expense of continued litigation, the Company and the plaintiffs agreed to resolve the Fee Application in exchange for a payment by the Company of $250,000 to Plaintiff’s counsel. The case is now closed.

v3.24.3

Operating Segments	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Operating Segments	Operating Segments Starting in 2024, the Company manages its operations based on one reportable operating segment: Insurance. Through the Insurance segment, the Company provides PPO and HMO plans to Medicare Advantage members in several states. These segment groupings are consistent with information used by the CODM, to assess performance and allocate resources. The operations of the Company are organized into the following segment: •Insurance Segment includes operations related to the Company's MA plans, which generally provide access to a wide network of primary care providers, specialists, and hospitals. Corporate/Other includes other clinical services not included in Medicare Advantage, Counterpart Health, and all other corporate overhead. Clinical services is comprised of Clover Care Services and other clinical services that are offered to eligible beneficiaries. The table below summarizes the Company's results by operating segment: Insurance Corporate/Other Eliminations Consolidated Total Three months ended September 30, 2024 (in thousands) Premiums earned, net (net of ceded premiums of $97) $ 322,579  $ —  $ —  $ 322,579  Other income 4,314  32,422  (28,329) 8,407  Intersegment revenues —  46,944  (46,944) —  Net medical claims incurred 251,643  4,442  (6,311) 249,774  Gross profit $ 75,250  $ 74,924  $ (68,962) $ 81,212  Total assets $ 408,381  $ 918,407  $ (673,775) $ 653,013  Insurance Corporate/Other Eliminations Consolidated Total Nine months ended September 30, 2024 (in thousands) Premiums earned, net (net of ceded premiums of $301) $ 1,014,201  $ —  $ —  $ 1,014,201  Other income 12,085  90,371  (82,489) 19,967  Intersegment revenues —  146,608  (146,608) —  Net medical claims incurred 767,125  14,345  (18,187) 763,283  Gross profit $ 259,161  $ 222,634  $ (210,910) $ 270,885  Total assets $ 408,381  $ 918,407  $ (673,775) $ 653,013  Insurance Corporate/Other Eliminations Consolidated Total Three months ended September 30, 2023 (in thousands) Premiums earned, net (net of ceded premiums of $106) $ 301,230  $ —  $ —  $ 301,230  Other income 3,338  14,218  (12,758) 4,798  Intersegment revenues —  43,335  (43,335) —  Net medical claims incurred 236,533  4,690  (5,438) 235,785  Gross profit $ 68,035  $ 52,863  $ (50,655) $ 70,243  Total assets $ 464,942  $ 905,477  $ (685,439) $ 684,980  Insurance Corporate/Other Eliminations Consolidated Total Nine months ended September 30, 2023 (in thousands) Premiums earned, net (net of ceded premiums of $341) $ 932,699  $ —  $ —  $ 932,699  Other income 7,192  45,732  (37,465) 15,459  Intersegment revenues —  112,220  (112,220) —  Net medical claims incurred 753,877  11,820  (10,861) 754,836  Gross profit $ 186,014  $ 146,132  $ (138,824) $ 193,322  Total assets $ 464,942  $ 905,477  $ (685,439) $ 684,980  A reconciliation of the reportable segments' gross profit to the Net loss from continuing operations included in the Condensed Consolidated Statements of Operations and Comprehensive Loss is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Gross profit $ 81,212  $ 70,243  $ 270,885  $ 193,322  Salaries and benefits 54,995  60,567  169,717  191,985  General and administrative expenses 35,201  41,030  124,194  140,384  Premium deficiency reserve expense (benefit) —  392  —  (6,556) Depreciation and amortization 339  557  987  1,835  Restructuring (recoveries) costs (538) 1,313  288  7,870  Change in fair value of warrants —  —  17  —  Interest expense —  —  —  7  Loss on investment —  —  467  —  Net loss from continuing operations $ (8,785) $ (33,616) $ (24,785) $ (142,203)

v3.24.3

Dividend Restrictions	9 Months Ended
	Sep. 30, 2024
Disclosure of Restrictions on Dividends, Loans and Advances Disclosure [Abstract]
Dividend Restrictions	Dividend Restrictions The Company's regulated insurance subsidiaries are subject to regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital and limit the timing and amount of dividends and other distributions that may be paid to their parent companies. Therefore, the Company's regulated insurance subsidiaries' ability to declare and pay dividends is limited by state regulations including obtaining prior approval by the New Jersey Department of Banking and Insurance. At September 30, 2024 and December 31, 2023, neither of the regulated insurance subsidiaries had been authorized nor paid any dividends.

v3.24.3

Restructuring Costs	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Costs	Restructuring costs On April 17, 2023, the Company announced it would implement certain business transformation initiatives, including an agreement to move its core MA operational platform to UST HealthProof’s (“UST HealthProof”) and additional corporate restructuring actions. The agreement with UST HealthProof includes the transition of certain of the Company’s plan operation functions in support of its Medicare Advantage members pursuant to a master services agreement. In addition to the arrangement with UST HealthProof, in April 2023 the Company conducted a reduction in force to better align its Selling, General, and Administrative cost structure with its revenue base. This restructuring resulted in the elimination of approximately 10% of the Company's workforce. The Company incurred costs related to these business transformation initiatives, which consisted of employee termination benefits, vendor related costs, and other costs, which are accounted for as exit and disposal costs and recorded pursuant to ASC 420, Exit or Disposal Cost Obligations. For those costs determined to be one-time termination benefits the Company established a liability for the restructuring related expenses when the plan was established, the remaining costs will be expensed as incurred. The Restructuring costs are presented in the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss, which were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Employee termination (recoveries) benefits $ (547) $ 58  $ (547) $ 4,620  Vendor related costs —  1,245  822  3,166  Other 9  10  13  84  Total restructuring (recoveries) costs $ (538) $ 1,313  $ 288  $ 7,870  UST HealthProof Transition As of September 30, 2024, the liability for employee termination benefits was recorded in Accrued salaries and benefits and the liability for vendor related costs and other expenses were recorded in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. The liability recorded reflects the Company's best estimate, which may be revised in subsequent periods as the restructuring progresses. The restructuring costs are recorded within the Corporate/Other operating segment. In addition, the Company incurred costs related to software impairment. These costs are recognized in Depreciation and amortization in the Condensed Consolidated Statements of Operations and Comprehensive Loss, and totaled less than $0.1 million for the three months and nine months ended September 30, 2024. For the three and nine months ended September 30, 2023, software impairment costs totaled $0.1 million. Employee Termination Benefits Vendor related costs Other Total (in thousands) Liability as of December 31, 2023 $ 1,781  $ 3,390  $ —  $ 5,171  (Recoveries) charges (547) 822  13  288  Cash payments (1,234) (1,307) (13) (2,554) Liability as of September 30, 2024 $ —  $ 2,905  $ —  $ 2,905  Total cumulative costs incurred as of September 30, 2024 $ 4,248  $ 5,761  $ 100  $ 10,109

v3.24.3

Discontinued Operations	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On December 1, 2023, the Company notified CMS that it would no longer participate as a REACH ACO in connection with the 2024 performance year. The Company’s exit from the ACO REACH Program was made after the Company determined that it is in its best interest to fully exit the ACO REACH Program starting with the 2024 performance year, and follows the Company's November 2022 announcement of a strategic reduction in the number of ACO REACH participating physicians in 2023. The nature of the remaining activities relate to the settlement with CMS related to prior performance years which is expected to be completed by the end of 2024. A summary of the carrying amounts of major assets and liabilities, which were classified as held for settlement in the Condensed Consolidated Balance Sheets, follows: September 30, 2024 December 31, 2023 (in thousands) Assets(1) Cash and cash equivalents $ —  $ 6,456  Surety bond and deposits —  55,089  Non-Insurance receivable 10,087  10,926  Total assets $ 10,087  $ 72,471  Liabilities(1) Unpaid claims $ 1,080  $ 2,856  Accrued salaries and benefits —  110  Non-Insurance performance year obligation, current 4,740  15,568  Non-Insurance payable 43,121  41,565  Total liabilities $ 48,941  $ 60,099  (1) The assets and liabilities of the disposal group are classified as current in the Condensed Consolidated Balance Sheet at September 30, 2024 as the settlement with CMS is expected to occur within one year. A summary of the results from discontinued operations included in the Condensed Consolidated Statements of Operations and Comprehensive Loss follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Revenues: Non-Insurance revenue $ (6,149) $ 176,038  $ (370) $ 575,311  Total revenues (6,149) 176,038  (370) 575,311  Operating Expenses: Net medical claims incurred (6,009) 183,174  (5,276) 573,567  General and administrative expenses 230  717  741  2,430  Restructuring costs —  —  297  —  Total operating expenses (5,779) 183,891  (4,238) 575,997  (Loss) gain from operations (370) (7,853) 3,868  (686) Net (loss) income $ (370) $ (7,853) $ 3,868  $ (686) A summary of cash flows from discontinued operations included in the Condensed Consolidated Statements of Cash Flows follows: Nine Months Ended September 30, 2024 2023 (in thousands) Net cash (used in) provided by operating activities $ (8,861) $ 34,060  Performance guarantees Certain of the Company's arrangements with third-party providers require it to guarantee the performance of its care network to CMS. As a result of the Company's participation in the ACO REACH Model, the Company determined that it was making a performance guarantee with respect to providers under the Non-Insurance arrangement that should be recognized in the financial statements. The performance guarantee identified relates to the Company guaranteeing the performance of the third-party medical providers. Thus, the contract with CMS is accounted for as a performance guarantee under ASC 460, Guarantees. At the inception of the performance year, the Company measures and recognizes the performance guarantee receivable and obligation, issued in this standalone arm's length transaction, using the practical expedient to fair value as set forth in ASC 460-10-30-2(a). The Company estimates the annualized benchmark, which is the amount recognized in both the Non-Insurance performance year receivable and the Non-Insurance performance year obligation, current. This is consistent with ASC 460-10-25-4, which provides that a guarantor shall recognize in its statement of financial position a liability for that guarantee. In addition, when the guarantee is issued in a standalone transaction for a premium, the offsetting entry should be considered received (such as cash or a receivable) according to ASC 460-10-25-4. Thus the Company recognizes the Non-Insurance performance year receivable on its balance sheets. To subsequently measure and recognize the performance guarantee, the Company follows ASC 460-10-35-2(b) and applies a systematic and rational approach to reflect its release from risk. Under this approach, the Company amortizes on a straight-line basis over the performance year, the obligation. The Company has determined this systematic and rational method is appropriate, as it matches the period in which the guarantee is fulfilled. In addition, ASC 460-10-35-2 provides further guidance on the subsequent measurement related to the Company's performance guarantee. Per ASC 460-10-35-2, depending on the nature of the guarantee, the guarantor's release from risk typically can be recognized over the term of the guarantee using one of three methods: (1) upon expiration or settlement, (2) by systematic or rational amortization, or (3) as the fair value of the guarantee changes. The Company has determined that method (2) is the appropriate method of recognition as discussed above. With respect to each performance year in which the ACO is a participant, the final consideration due to the ACO from CMS ("shared savings") or the consideration due to CMS from the ACO ("shared loss") is reconciled in the subsequent years following the performance year. The shared savings or loss is measured periodically and will be applied to the Non-Insurance performance obligation, current or Non-Insurance performance receivable if the Company is in a probable loss position or probable savings position, respectively. The ACO has entered into an agreement with CMS and a third-party to cover the financial threshold determined by CMS. In April 2021, the Company began participating in the Global and Professional Direct Contracting of the Centers for Medicare & Medicaid Services ("CMS"), which utilizes a structured model intended to reduce expenditures and preserve or enhance quality of care for people with Medicare fee-for-service ("FFS"). CMS rebranded the DC Model and renamed the model the ACO Realizing Equity, Access, and Community Health (REACH) Model ("ACO REACH Model") effective January 1, 2023. As a participating entity in the DC Model, referred to as the ACO REACH Model at January 1, 2023, with a global risk arrangement, the Company assumed the responsibility of guaranteeing the performance of its care network. The ACO REACH Model is intended to reduce administrative burden and support a focus on complex, chronically ill patients. On December 1, 2023, the Company notified CMS that it will no longer participate as a REACH ACO in connection with the 2024 performance year. The Company’s exit from the ACO REACH Program was made after the Company determined that it is in the Company's best interest to fully exit the ACO REACH Program, and follows its November 2022 announcement of a strategic reduction in the number of ACO REACH participating physicians in 2023. Certain of the Company's arrangements with third-party providers require it to guarantee the performance of its care network to CMS, which, if not obtained, could potentially result in payment to CMS. The Non-Insurance performance year obligation and receivable are amortized on a straight-line basis for the amount that represents the completed performance. The Company is unable to estimate the maximum potential amount of future payments under the guarantee. This is attributable to the stop-loss arrangement and the corridors (tiered levels) in the arrangement. A certain percentage of these arrangements will still be the responsibility of the Company, in addition to a number of variables that are not reasonable for the Company to estimate, such as, but not limited to, risk ratings and benchmark trends that have an inestimable impact on the estimate of future payments. For additional information, see Note 2 (Summary of Significant Accounting Policies) and Note 20 (Non-Insurance) in the 2023 Form 10-K. The tables below include the financial statement impacts of the performance guarantee: September 30, 2024 December 31, 2023 (in thousands) Non-Insurance performance year obligation (1) $ 4,740  $ 15,568  (1) This obligation represents the consideration due to providers, net of the shared savings or loss for the period and amortization of the liability. Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Amortization of the Non-Insurance performance year receivable $ —  $ (182,753) $ —  $ (556,211) Amortization of the Non-Insurance performance year obligation —  182,753  —  556,211  Non-Insurance revenue (6,149) 176,038  (370) 575,311

v3.24.3

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events None.

v3.24.3

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (9,155)	$ 7,408	$ (19,170)	$ (41,469)	$ (28,814)	$ (72,606)

v3.24.3

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

v3.24.3

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Company's condensed consolidated financial statements have been prepared in conformity with the generally accepted accounting principles in the United States ("GAAP") as well as in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and include the accounts of the Company and its wholly-owned subsidiaries. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, necessary for a fair presentation of its financial condition and its results of operations for the periods presented. All material intercompany balances and transactions have been eliminated in consolidating these financial statements. Investments over which we exercise significant influence, but do not control, are accounted for using the applicable accounting treatment based on the nature of the investment. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the 2023 Form 10-K.
Use of estimates	Use of estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and the accompanying notes. The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, reinsurance, premium deficiency reserve, stock-based compensation, recoveries from third parties for coordination of benefits, and final determination of medical cost adjustment pools.
Reclassifications	Reclassifications Certain amounts in the prior year's Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current year's presentation, primarily related to Surety bonds and deposits and Change in restricted cash related to surety bonds, deposits, and escrow accounts.
Discontinued Operations	Discontinued Operations The results of operations for the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Assets and liabilities related to the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented in the Condensed Consolidated Balance Sheets. Refer to Note 17 (Discontinued Operations) for additional information.
Equity method of accounting and variable interest entities	Equity method of accounting and variable interest entities Investments in entities in which the Company does not have control but its ownership falls between 20.0% and 50.0%, or it has the ability to exercise significant influence over operating and financial policies, are accounted for under the equity method of accounting. The Company continuously assesses its partially-owned entities to determine if these entities are variable interest entities ("VIEs") and, if so, whether the Company is the primary beneficiary and, therefore, required to consolidate the VIE. To make this determination, the Company applies a qualitative approach to determine whether the Company has both the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. If the Company has an interest in a VIE but is determined to not be the primary beneficiary, the Company accounts for the interest under the equity method of accounting. When the Company's carrying value in an equity method investee company is reduced to zero, no further losses are recorded in the Company's condensed consolidated financial statements unless the Company guaranteed obligations of the investee company or has committed additional funding. When the investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
Segment information	Segment information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. At September 30, 2024, the Company has one reportable segment, Insurance. Beginning in 2024, the Company exited the ACO REACH Model and as a direct result, the reportable operating segment formerly known as Non-Insurance no longer meets the criteria of a required reportable operating segment.
Capitalized software development costs - cloud computing arrangements	Capitalized software development costs - cloud computing arrangements The Company's cloud computing arrangements are mostly comprised of hosting arrangements that are mostly service contracts, whereby the Company gains remote access to use enterprise software hosted by the vendor or another third party on an as-needed basis for a period of time in exchange for a subscription fee. Implementation costs for cloud computing arrangements are capitalized if certain criteria are met and consist of internal and external costs directly attributable to developing and configuring cloud computing software for its intended use. These capitalized implementation costs are presented in the Condensed Consolidated Balance Sheets within Prepaid expenses and are generally amortized over the fixed, non-cancelable term of the associated hosting arrangement on a straight-line basis.
Deferred acquisition costs	Deferred acquisition costs Acquisition costs directly related to the successful acquisition of new business, which are primarily made up of commissions costs, are deferred and subsequently amortized. Deferred acquisition costs are recorded within Other assets, current in the Condensed Consolidated Balance Sheets and are amortized over the estimated life of the related contracts. The amortization of deferred acquisition costs is recorded within General and administrative expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
Restructuring Activities	Restructuring Activities Restructuring related expenses, which are recorded within Restructuring costs in the Condensed Consolidated Statements of Operations and Comprehensive Loss, include employee termination benefits, vendor costs associated with restructuring activities, and other costs associated with the business transformation initiatives. Restructuring costs are determined based on estimates, which are prepared at the time the restructuring actions are approved by management and are periodically reviewed and updated for changes in estimates. The Company applies the provisions of ASC 420, Exit or Disposal Cost Obligations ("ASC 420") as these costs meet the criteria of a one-time benefit. Under ASC 420-10, the Company establishes a liability for a cost associated with an exit or disposal activity, including employee termination benefits and other restructuring related costs, when the liability is incurred, rather than at the date that the Company commits to an exit plan. At each reporting date, there is an evaluation of the liability to ensure the amount is still appropriate. See Note 16 (Restructuring costs) for further discussion.
Recent accounting pronouncements	Recent accounting pronouncements Recently adopted accounting pronouncements There have been no new accounting pronouncements adopted during the nine months ended September 30, 2024 that had a material impact on the Company's condensed consolidated financial statements. Accounting pronouncements effective in future periods In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement—Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation—Stock Compensation (Topic 718); Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280—General Revision of Regulation S-X: Income or Loss Applicable to Common Stock (“ASU 2023-03”). This ASU amends or supersedes various SEC paragraphs within the applicable codification to conform to past SEC staff announcements. This ASU does not provide any new guidance. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on its condensed consolidated financial statements and related disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update aim to improve reportable segment disclosures by requiring enhanced disclosures around significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual disclosures about segment profit or loss must be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years beginning after December 15, 2024. A public entity should apply ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update aim to provide more transparency regarding tax disclosures mainly related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its condensed consolidated financial statements and related disclosures.

v3.24.3

Investment Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Investment Securities Reconciliation	The following tables present amortized cost and fair values of investments at September 30, 2024 and December 31, 2023, respectively: September 30, 2024 Amortized cost Accumulated unrealized gains Accumulated unrealized losses Fair value (in thousands) Investment securities, held-to-maturity U.S. government and government agencies and authorities $ 14,309  $ 7  $ (123) $ 14,193  Investment securities, available-for-sale U.S. government and government agencies and authorities 141,551  1,396  (1,258) 141,689  Corporate debt securities 83,321  714  (32) 84,003  Other 1,663  32  —  1,695  Total held-to-maturity and available-for-sale investment securities $ 240,844  $ 2,149  $ (1,413) $ 241,580  December 31, 2023 Amortized cost Accumulated unrealized gains Accumulated unrealized losses Fair value (in thousands) Investment securities, held-to-maturity U.S. government and government agencies and authorities $ 7,695  $ —  $ (225) $ 7,470  Investment securities, available-for-sale U.S. government and government agencies and authorities 126,071  713  (3,070) 123,714  Corporate debt securities 95,354  165  (176) 95,343  Other 1,855  —  (2) 1,853  Total held-to-maturity and available-for-sale investment securities $ 230,975  $ 878  $ (3,473) $ 228,380
Schedule of Amortized Cost and Fair Value of Debt Securities	The following table presents the amortized cost and fair value of debt securities at September 30, 2024, by contractual maturity: September 30, 2024 Held-to-maturity Available-for-sale Amortized cost Fair value Amortized cost Fair value (in thousands) Due within one year $ 15  $ 15  $ 43,695  $ 43,302  Due after one year through five years 14,183  14,083  182,840  184,085  Due after five years through ten years —  —  —  —  Due after ten years 111  95  —  —  Total $ 14,309  $ 14,193  $ 226,535  $ 227,387
Schedule of Net Investment Income	For the three and nine months ended September 30, 2024 and 2023, respectively, net investment income, which is included in Other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, was derived from the following sources: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Cash and cash equivalents $ 4,488  $ 1,944  $ 10,120  $ 5,978  Short-term investments 232  605  548  1,920  Investment securities 2,099  1,840  6,351  5,322  Investment income, net $ 6,819  $ 4,389  $ 17,019  $ 13,220
Schedule of Gross Unrealized Losses and Fair Value for Fixed Maturities in a Continuous Unrealized Loss Position	Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at September 30, 2024, and December 31, 2023, respectively: September 30, 2024 Less than 12 months Greater than 12 months Total Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss (in thousands, except number of positions) U.S. government and government agencies and authorities $ 10,269  $ (40) $ 39,379  $ (1,341) $ 49,648  $ (1,381) Corporate debt securities 19,118  (30) 4,290  (2) 23,408  (32) Total $ 29,387  $ (70) $ 43,669  $ (1,343) $ 73,056  $ (1,413) Number of positions 21  19  40  December 31, 2023 Less than 12 months Greater than 12 months Total Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss (in thousands, except number of positions) U.S. government and government agencies and authorities $ 12,584  $ (32) $ 61,628  $ (3,259) $ 74,212  $ (3,291) Corporate debt securities 61,007  (175) 5,017  (7) 66,024  (182) Total $ 73,591  $ (207) $ 66,645  $ (3,266) $ 140,236  $ (3,473) Number of positions 69  27  96
Schedule of Realized Gain (Loss) on Investment Securities	Proceeds from sales and maturities of investment securities, inclusive of short-term investments, and related gross realized gains (losses) which are included in Other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, were as follows for the three and nine months ended September 30, 2024 and 2023, respectively: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Proceeds from sales of investment securities $ 47,804  $ —  $ 47,804  $ 60,436  Proceeds from maturities of investment securities 42,137  32,240  108,788  139,122  Gross realized gains 170  —  174  39  Gross realized losses —  —  —  (19) Net realized gains $ 170  $ —  $ 174  $ 20

v3.24.3

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurements for Items	The following tables present a summary of fair value measurements for financial instruments at September 30, 2024 and December 31, 2023, respectively: September 30, 2024 Level 1 Level 2 Level 3 Total fair value (in thousands) U.S. government and government agencies $ —  $ 141,689  $ —  $ 141,689  Corporate debt securities —  84,003  —  84,003  Other —  1,695  —  1,695  Warrants receivable —  —  797  797  Total assets at fair value $ —  $ 227,387  $ 797  $ 228,184  December 31, 2023 Level 1 Level 2 Level 3 Total fair value (in thousands) U.S. government and government agencies $ —  $ 123,714  $ —  $ 123,714  Corporate debt securities —  95,343  —  95,343  Other 1,853  —  —  1,853  Warrants receivable —  —  814  814  Total assets at fair value $ 1,853  $ 219,057  $ 814  $ 221,724
Schedule of Changes in Balances of Level 3 Financial Liabilities	The changes in balances of Clover's Level 3 financial assets and liabilities during the nine months ended September 30, 2024 were as follows: Warrants receivable Total (in thousands) Balance, December 31, 2023 $ 814  $ 814  Total unrealized losses 17  17  Balance, September 30, 2024 $ 797  $ 797

v3.24.3

Unpaid Claims (Tables)	9 Months Ended
	Sep. 30, 2024
Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]
Schedule of Activity in the Liability for Unpaid Claims and Claims Adjustment Expense	Activity within the liability for Unpaid claims, including claims adjustment expenses, for the nine months ended September 30, 2024 and 2023, respectively, is summarized as follows: Nine Months Ended September 30, 2024 2023 (in thousands) Gross and net balance, beginning of period (1) $ 137,100  $ 137,395  Incurred related to: Current year 780,461  750,705  Prior years (31,523) (7,689) Total incurred 748,938  743,016  Paid related to: Current year 622,126  646,322  Prior years 96,502  120,859  Total paid 718,628  767,181  Gross and net balance, end of period (1) $ 167,410  $ 113,230  (1)    Includes amounts due to related parties.

v3.24.3

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share-Based Payment Arrangement Activity	The maximum number of shares of the Company's common stock reserved for issuance over the term of the Plans, shares outstanding under the Plans, and shares remaining under the Plans at September 30, 2024 were as follows: September 30, 2024 Shares Authorized Under Plans Shares Outstanding Under Plans Shares Remaining Under Plans 2014 Plan 54,402,264  34,457,710  N/A 2020 Plan 86,604,581  39,844,072  19,817,658  2020 MIP 33,426,983  23,398,889  —  Inducement Plan 11,000,000  6,293,605  —
Schedule of Stock-Based Compensation Cost	Compensation cost presented in Salaries and benefits in the Condensed Consolidated Statements of Operations and Comprehensive Loss were as follows: Three Months Ended September 30, 2024 2023 (in thousands) Stock options $ 384  $ 559  RSUs 21,074  20,603  PRSUs 6,170  11,851  ESPP 360  57  Total compensation cost recognized for stock-based compensation plans $ 27,988  $ 33,070  Nine Months Ended September 30, 2024 2023 (in thousands) Stock options $ 1,532  $ 2,648  RSUs 62,391  62,539  PRSUs 20,327  42,444  ESPP 436  164  Total compensation cost recognized for stock-based compensation plans $ 84,686  $ 107,795
Schedule of Stock Option Activity	A summary of option activity under the 2020 Plan during the nine months ended September 30, 2024, was as follows: Number of stock options Weighted-average exercise price Outstanding, January 1, 2024 952,900  $ 8.88  Granted —  —  Exercised —  —  Forfeited (131,212) 8.88  Outstanding, September 30, 2024 821,688  $ 8.88  A summary of stock option activity under the 2014 Plan during the nine months ended September 30, 2024, was as follows: Number of stock options Weighted-average exercise price Outstanding, January 1, 2024 24,041,753  $ 1.45  Granted —  —  Exercised (210,555) 1.16  Forfeited (120,650) 3.44  Outstanding, September 30, 2024 23,710,548  $ 2.73
Schedule of Total RSU Activity	A summary of total RSU activity is presented below: Number of RSUs Weighted-average grant date fair value per share Outstanding, January 1, 2024 56,928,405  $ 4.28  Granted 17,639,741  0.97  Released (17,249,172) 4.56  Forfeited (7,625,408) 1.93  Outstanding, September 30, 2024 49,693,566  $ 3.37
Schedule of Weighted Average Grant Date Fair Value of Performance Restricted Stock Units	The assumptions that the Company used in the Monte Carlo model to determine the grant date fair value of Market PRSUs granted for the year ended December 31, 2021, were as follows: Year ended December 31, 2021 Expected volatility (1) 40.7  % Risk-free interest rate (2) 0.5  Dividend yield (3) —  (1) Expected volatility is based on a blend of peer group company historical data adjusted for the Company's leverage. (2) Risk-free interest rate based on U.S. Treasury yields with a term equal to the remaining Performance Period as of the grant date. (3) Dividend yield was assumed to be zero as the Company does not anticipate paying dividends.
Schedule of Total Performance Restricted Stock Units	A summary of PRSU activity is presented below: Number of PRSUs Weighted-average grant date fair value per share Non-vested, January 1, 2024 32,131,532  $ 8.36  Granted during 2024 —  —  Adjustment for performance condition achieved(1) 341,459  0.95  Vested (2,389,515) 1.14  Forfeited (315,292) 1.56  Non-vested at September 30, 2024 29,768,184  $ 8.93  (1) Represents an increase in the number of original CLOV performance share units awarded based on final achievement at the end of the performance period of such awards.
Schedule of Assumptions Used in ESPP Fair Value Determination	The assumptions that the Company used in the Black-Scholes option-pricing model to determine the fair value of the purchase rights under the ESPP for the most recent offering period, is as follows: Offering period from May 22, 2024 to November 21, 2024 Weighted-average risk-free interest rate 5.4  % Expected term (in years) 0.50 Expected volatility 64.0  %

v3.24.3

Net Income (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income (Loss) per Share	Basic and diluted net loss per share from continuing operations attributable to Class A common stockholders and Class B common stockholders (collectively, "Common Stockholders") for the years indicated were calculated as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands, except for per share and share amounts) Numerator: Net loss from continuing operations attributable to Common Stockholders $ (8,785) $ (33,616) $ (24,785) $ (142,203) Net (loss) income from discontinued operations attributable to Common Stockholders (370) (7,853) 3,868  (686) Denominator: Basic weighted average number of common shares and common share equivalents outstanding 490,180,103  480,770,283  488,501,812  480,921,520  Dilutive shares: RSU N/A N/A N/A N/A PRSU N/A N/A N/A N/A Stock Options N/A N/A N/A N/A Weighted average shares used in computing net income per share of common stock, diluted 490,180,103  480,770,283  488,501,812  480,921,520  Basic loss per share from continuing operations $ (0.02) $ (0.07) $ (0.05) $ (0.30) Basic earnings (loss) per share from discontinued operations 0.00 (0.02) 0.01 0.00 Diluted loss per share from continuing operations (0.02) (0.07) (0.05) (0.30) Diluted earnings (loss) per share from discontinued operations 0.00 (0.02) 0.01 0.00
Schedule of Antidilutive Securities Excluded from Diluted Net Loss Per Share	The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income (loss) per share of common stock: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Options to purchase common stock 24,532,236  25,138,347  24,532,236  25,138,347  RSUs 49,693,566  55,544,997  49,693,566  55,544,997  PRSUs 29,768,184  30,224,866  29,768,184  30,224,866  Total potentially dilutive shares excluded from computation of net income (loss) per share 103,993,986  110,908,210  103,993,986  110,908,210

v3.24.3

Operating Segments (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The table below summarizes the Company's results by operating segment: Insurance Corporate/Other Eliminations Consolidated Total Three months ended September 30, 2024 (in thousands) Premiums earned, net (net of ceded premiums of $97) $ 322,579  $ —  $ —  $ 322,579  Other income 4,314  32,422  (28,329) 8,407  Intersegment revenues —  46,944  (46,944) —  Net medical claims incurred 251,643  4,442  (6,311) 249,774  Gross profit $ 75,250  $ 74,924  $ (68,962) $ 81,212  Total assets $ 408,381  $ 918,407  $ (673,775) $ 653,013  Insurance Corporate/Other Eliminations Consolidated Total Nine months ended September 30, 2024 (in thousands) Premiums earned, net (net of ceded premiums of $301) $ 1,014,201  $ —  $ —  $ 1,014,201  Other income 12,085  90,371  (82,489) 19,967  Intersegment revenues —  146,608  (146,608) —  Net medical claims incurred 767,125  14,345  (18,187) 763,283  Gross profit $ 259,161  $ 222,634  $ (210,910) $ 270,885  Total assets $ 408,381  $ 918,407  $ (673,775) $ 653,013  Insurance Corporate/Other Eliminations Consolidated Total Three months ended September 30, 2023 (in thousands) Premiums earned, net (net of ceded premiums of $106) $ 301,230  $ —  $ —  $ 301,230  Other income 3,338  14,218  (12,758) 4,798  Intersegment revenues —  43,335  (43,335) —  Net medical claims incurred 236,533  4,690  (5,438) 235,785  Gross profit $ 68,035  $ 52,863  $ (50,655) $ 70,243  Total assets $ 464,942  $ 905,477  $ (685,439) $ 684,980  Insurance Corporate/Other Eliminations Consolidated Total Nine months ended September 30, 2023 (in thousands) Premiums earned, net (net of ceded premiums of $341) $ 932,699  $ —  $ —  $ 932,699  Other income 7,192  45,732  (37,465) 15,459  Intersegment revenues —  112,220  (112,220) —  Net medical claims incurred 753,877  11,820  (10,861) 754,836  Gross profit $ 186,014  $ 146,132  $ (138,824) $ 193,322  Total assets $ 464,942  $ 905,477  $ (685,439) $ 684,980
Schedule of Reconciliation of Revenue from Segments to Consolidated	A reconciliation of the reportable segments' gross profit to the Net loss from continuing operations included in the Condensed Consolidated Statements of Operations and Comprehensive Loss is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Gross profit $ 81,212  $ 70,243  $ 270,885  $ 193,322  Salaries and benefits 54,995  60,567  169,717  191,985  General and administrative expenses 35,201  41,030  124,194  140,384  Premium deficiency reserve expense (benefit) —  392  —  (6,556) Depreciation and amortization 339  557  987  1,835  Restructuring (recoveries) costs (538) 1,313  288  7,870  Change in fair value of warrants —  —  17  —  Interest expense —  —  —  7  Loss on investment —  —  467  —  Net loss from continuing operations $ (8,785) $ (33,616) $ (24,785) $ (142,203)

v3.24.3

Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Charges	The Restructuring costs are presented in the Company's Condensed Consolidated Statements of Operations and Comprehensive Loss, which were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Employee termination (recoveries) benefits $ (547) $ 58  $ (547) $ 4,620  Vendor related costs —  1,245  822  3,166  Other 9  10  13  84  Total restructuring (recoveries) costs $ (538) $ 1,313  $ 288  $ 7,870
Schedule of Other Restructuring and Related Costs	The restructuring costs are recorded within the Corporate/Other operating segment. In addition, the Company incurred costs related to software impairment. These costs are recognized in Depreciation and amortization in the Condensed Consolidated Statements of Operations and Comprehensive Loss, and totaled less than $0.1 million for the three months and nine months ended September 30, 2024. For the three and nine months ended September 30, 2023, software impairment costs totaled $0.1 million. Employee Termination Benefits Vendor related costs Other Total (in thousands) Liability as of December 31, 2023 $ 1,781  $ 3,390  $ —  $ 5,171  (Recoveries) charges (547) 822  13  288  Cash payments (1,234) (1,307) (13) (2,554) Liability as of September 30, 2024 $ —  $ 2,905  $ —  $ 2,905  Total cumulative costs incurred as of September 30, 2024 $ 4,248  $ 5,761  $ 100  $ 10,109

v3.24.3

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	A summary of the carrying amounts of major assets and liabilities, which were classified as held for settlement in the Condensed Consolidated Balance Sheets, follows: September 30, 2024 December 31, 2023 (in thousands) Assets(1) Cash and cash equivalents $ —  $ 6,456  Surety bond and deposits —  55,089  Non-Insurance receivable 10,087  10,926  Total assets $ 10,087  $ 72,471  Liabilities(1) Unpaid claims $ 1,080  $ 2,856  Accrued salaries and benefits —  110  Non-Insurance performance year obligation, current 4,740  15,568  Non-Insurance payable 43,121  41,565  Total liabilities $ 48,941  $ 60,099  (1) The assets and liabilities of the disposal group are classified as current in the Condensed Consolidated Balance Sheet at September 30, 2024 as the settlement with CMS is expected to occur within one year. A summary of the results from discontinued operations included in the Condensed Consolidated Statements of Operations and Comprehensive Loss follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Revenues: Non-Insurance revenue $ (6,149) $ 176,038  $ (370) $ 575,311  Total revenues (6,149) 176,038  (370) 575,311  Operating Expenses: Net medical claims incurred (6,009) 183,174  (5,276) 573,567  General and administrative expenses 230  717  741  2,430  Restructuring costs —  —  297  —  Total operating expenses (5,779) 183,891  (4,238) 575,997  (Loss) gain from operations (370) (7,853) 3,868  (686) Net (loss) income $ (370) $ (7,853) $ 3,868  $ (686) A summary of cash flows from discontinued operations included in the Condensed Consolidated Statements of Cash Flows follows: Nine Months Ended September 30, 2024 2023 (in thousands) Net cash (used in) provided by operating activities $ (8,861) $ 34,060
Schedule of Performance Guarantees	The tables below include the financial statement impacts of the performance guarantee: September 30, 2024 December 31, 2023 (in thousands) Non-Insurance performance year obligation (1) $ 4,740  $ 15,568  (1) This obligation represents the consideration due to providers, net of the shared savings or loss for the period and amortization of the liability. Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Amortization of the Non-Insurance performance year receivable $ —  $ (182,753) $ —  $ (556,211) Amortization of the Non-Insurance performance year obligation —  182,753  —  556,211  Non-Insurance revenue (6,149) 176,038  (370) 575,311

v3.24.3

Summary of Significant Accounting Policies (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)
Accounting Policies [Line Items]
Number of reporting segments (in segments) | segment			1
General and Administrative Expense
Accounting Policies [Line Items]
Amortization expense of deferred acquisition costs | $	$ 2.7	$ 0.6	$ 5.5	$ 5.8

v3.24.3

Investment Securities - Schedule of Present Cost or Amortized Cost and Fair Values of Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Investment securities, held-to-maturity
Amortized cost	$ 14,309
Fair value	14,193
Total held-to-maturity and available-for-sale investment securities
Amortized cost	240,844	$ 230,975
Accumulated unrealized gains	2,149	878
Accumulated unrealized losses	(1,413)	(3,473)
Fair value	241,580	228,380
U.S. government and government agencies and authorities
Investment securities, held-to-maturity
Amortized cost	14,309	7,695
Accumulated unrealized gains	7	0
Accumulated unrealized losses	(123)	(225)
Fair value	14,193	7,470
Investment securities, available-for-sale
Amortized cost	141,551	126,071
Accumulated unrealized gains	1,396	713
Accumulated unrealized losses	(1,258)	(3,070)
Fair value	141,689	123,714
Corporate debt securities
Investment securities, available-for-sale
Amortized cost	83,321	95,354
Accumulated unrealized gains	714	165
Accumulated unrealized losses	(32)	(176)
Fair value	84,003	95,343
Other
Investment securities, available-for-sale
Amortized cost	1,663	1,855
Accumulated unrealized gains	32	0
Accumulated unrealized losses	0	(2)
Fair value	$ 1,695	$ 1,853

v3.24.3

Investment Securities - Schedule of Amortized Cost and Fair Value of Debt Securities (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Debt Securities, Held-to-maturity, Maturity, Amortized Cost, Net [Abstract]
Due within one year	$ 15
Due after one year through five years	14,183
Due after five years through ten years	0
Due after ten years	111
Amortized cost	14,309
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Due within one year	15
Due after one year through five years	14,083
Due after five years through ten years	0
Due after ten years	95
Total	14,193
Debt Securities, Available-for-sale, Amortized Cost [Abstract]
Due within one year	43,695
Due after one year through five years	182,840
Due after five years through ten years	0
Due after ten years	0
Total	226,535
Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]
Due within one year	43,302
Due after one year through five years	184,085
Due after five years through ten years	0
Due after ten years	0
Total	$ 227,387

v3.24.3

Investment Securities - Schedule of Net Investment Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Separate Account Investment [Line Items]
Investment income, net	$ 6,819	$ 4,389	$ 17,019	$ 13,220
Cash and cash equivalents
Fair Value, Separate Account Investment [Line Items]
Investment income, net	4,488	1,944	10,120	5,978
Short-term investments
Fair Value, Separate Account Investment [Line Items]
Investment income, net	232	605	548	1,920
Investment securities
Fair Value, Separate Account Investment [Line Items]
Investment income, net	$ 2,099	$ 1,840	$ 6,351	$ 5,322

v3.24.3

Investment Securities - Schedule of Gross Unrealized Losses and Fair Value (Details) $ in Thousands	Sep. 30, 2024 USD ($) position	Dec. 31, 2023 USD ($) position
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Less than 12 months, Fair value	$ 29,387	$ 73,591
Less than 12 months, Unrealized loss	(70)	(207)
Greater than 12 months, Fair Value	43,669	66,645
Greater than 12 months, Unrealized loss	(1,343)	(3,266)
Total, Fair value	73,056	140,236
Total, Unrealized Loss	$ (1,413)	$ (3,473)
Less than 12 months, Number of positions | position	21	69
Greater than 12 months, Number of positions | position	19	27
Total, Number of positions | position	40	96
U.S. government and government agencies and authorities
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Less than 12 months, Fair value	$ 10,269	$ 12,584
Less than 12 months, Unrealized loss	(40)	(32)
Greater than 12 months, Fair Value	39,379	61,628
Greater than 12 months, Unrealized loss	(1,341)	(3,259)
Total, Fair value	49,648	74,212
Total, Unrealized Loss	(1,381)	(3,291)
Corporate debt securities
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Less than 12 months, Fair value	19,118	61,007
Less than 12 months, Unrealized loss	(30)	(175)
Greater than 12 months, Fair Value	4,290	5,017
Greater than 12 months, Unrealized loss	(2)	(7)
Total, Fair value	23,408	66,024
Total, Unrealized Loss	$ (32)	$ (182)

v3.24.3

Investment Securities - Additional Information (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Held-to-maturity debt securities, allowance for credit loss	$ 0	$ 0
Available-for-sale debt securities, allowance for credit loss	0	0
Deposits with various states and regulatory bodies	$ 14,900,000	$ 14,700,000

v3.24.3

Investment Securities -Schedule of Proceeds from Sales and Maturities of Investment Securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Proceeds from sales of investment securities	$ 47,804	$ 0	$ 47,804	$ 60,436
Proceeds from maturities of investment securities	42,137	32,240	108,788	139,122
Gross realized gains	170	0	174	39
Gross realized losses	0	0	0	(19)
Net realized gains	$ 170	$ 0	$ 174	$ 20

v3.24.3

Fair Value Measurements - Schedule of Fair Value Measurements for Items (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	$ 228,184	$ 221,724
Warrants receivable
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants receivable	797	814
U.S. government and government agencies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	141,689	123,714
Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	84,003	95,343
Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	1,695	1,853
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	0	1,853
Level 1 | Warrants receivable
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants receivable	0	0
Level 1 | U.S. government and government agencies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	0	0
Level 1 | Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	0	0
Level 1 | Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	0	1,853
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	227,387	219,057
Level 2 | Warrants receivable
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants receivable	0	0
Level 2 | U.S. government and government agencies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	141,689	123,714
Level 2 | Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	84,003	95,343
Level 2 | Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	1,695	0
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	797	814
Level 3 | Warrants receivable
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants receivable	797	814
Level 3 | U.S. government and government agencies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	0	0
Level 3 | Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	0	0
Level 3 | Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities	$ 0	$ 0

v3.24.3

Fair Value Measurements - Schedule of Changes in Balances of Level 3 Financial Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (loss) on investments
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 814
Total unrealized losses	17
Ending balance	797
Level 3 | Warrants receivable
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	814
Total unrealized losses	17
Ending balance	$ 797

v3.24.3

Fair Value Measurements - Additional Information (Details) - Level 3 - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial asset or liabilities transfer in and out	$ 0	$ 0
Unrealized gain (loss)	(17,000)
Private warrants
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants receivable			$ 800,000
Unrealized gain (loss)	$ (100,000)

v3.24.3

Healthcare Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Healthcare receivables	$ 37,314	$ 64,164

v3.24.3

Related-Party Transactions (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Sep. 23, 2020	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Net medical claims incurred		$ 249,774	$ 235,785	$ 763,283	$ 754,836
General and administrative expenses		35,201	41,030	124,194	140,384
Related party | CarePoint Health Contract
Related Party Transaction [Line Items]
Net medical claims incurred		2,500	3,200	5,300	9,700
Other liabilities		1,300		1,300		$ 1,400
Related party | Medical Records Exchange, LLC
Related Party Transaction [Line Items]
General and administrative expenses		100	300	500	600
Related party | Thyme Care, Inc.
Related Party Transaction [Line Items]
Other liabilities		3,000		3,000		$ 200
General and administrative expenses		$ 900	$ 900	$ 3,200	$ 1,700
Number of shares purchased (in shares)	1,773,049
Equity interest percentage (less than)	5.00%	5.00%		5.00%
Other assets, fair value		$ 1,800		$ 1,800

v3.24.3

Unpaid Claims - Schedule of Activity in the Liability for Unpaid Claims and Claims Adjustment Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Gross and net balance, beginning of period	$ 137,100	$ 137,395
Incurred related to:
Current year	780,461	750,705
Prior years	(31,523)	(7,689)
Total incurred	748,938	743,016
Paid related to:
Current year	622,126	646,322
Prior years	96,502	120,859
Total paid	718,628	767,181
Gross and net balance, end of period	$ 167,410	$ 113,230

v3.24.3

Unpaid Claims - Additional information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Short-duration Insurance Contracts, Discounted Liabilities [Line Items]
Unpaid claims	$ 167,410	$ 113,230	$ 137,100	$ 137,395
Incurred claims paid	96,502	120,859
Unfavorable (favorable) development	$ (31,523)	$ (7,689)
Percentage of current year medical claims paid as a percent of current year net medical claims	0.797	0.861
Insurance Operations
Short-duration Insurance Contracts, Discounted Liabilities [Line Items]
Unpaid claims	$ 167,400

v3.24.3

Stockholders' Equity and Convertible Preferred Stock (Details) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	May 06, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) vote $ / shares shares	Dec. 31, 2023 shares
Class of Stock [Line Items]
Treasury stock, shares held (in shares)			16,817,010	7,912,750
Stock repurchased during period (in shares)			1,838,309
Stock repurchased during period | $		$ 1,772	$ 1,800
Preferred stock, shares authorized (in shares)			25,000,000
Preferred stock par value, (in dollars per share) | $ / shares			$ 0.0001
Preferred stock, shares issued (in shares)			0
Preferred stock, shares outstanding (in shares)			0
Common Class A
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			2,500,000,000	2,500,000,000
Common stock, shares, issued (in shares)			411,256,965	401,183,882
Common stock, shares, outstanding (in shares)			411,256,965	401,183,882
Common stock, number of voting rights per share (in votes) | vote			1
Amount of stock repurchase plan authorized | $	$ 20,000
Stock repurchase period	2 years
Common Class B
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			500,000,000	500,000,000
Common stock, shares, issued (in shares)			89,032,305	87,867,732
Common stock, shares, outstanding (in shares)			89,032,305	87,867,732
Common stock, number of voting rights per share (in votes) | vote			10

v3.24.3

Variable Interest Entity and Equity Method of Accounting (Details) - USD ($)		3 Months Ended		9 Months Ended
	Feb. 04, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2024	Jan. 23, 2023
Class of Stock [Line Items]
Gain (loss) on investments		$ 0	$ 0	$ (467,000)	$ 0
Charter Bioscience Inc.
Class of Stock [Line Items]
Gain (loss) on investments		$ 0	$ 0	$ 500,000	$ 0
Equity method investment						$ 0
Second Private Capital Transaction | Charter Bioscience Inc.
Class of Stock [Line Items]
Ownership percentage							23.92%
Private Capital Transaction | Charter Bioscience Inc.
Class of Stock [Line Items]
Ownership percentage	25.46%
Preferred stock | Second Private Capital Transaction | Charter Bioscience Inc.
Class of Stock [Line Items]
Net proceeds from sale of stock	$ 17,900,000
Sale of stock, number of shares issued in transaction (in shares)	16,210,602

v3.24.3

Employee Benefit Plans - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jan. 06, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employer matching contribution, percent of match				100.00%
Employer matching contribution, percent of employees' gross pay				4.00%
Employer maximum annual contributions per employee, percent				4.00%
Employer discretionary contribution amount		$ 500,000	$ 500,000	$ 1,600,000	$ 1,400,000
Employers matching contribution, vesting percentage				100.00%
Total compensation cost recognized for stock-based compensation plans				$ 84,686,000	107,795,000
Unvested stock options, unrecognized stock-based compensation		383,400,000		$ 383,400,000
Cost not yet recognized, period for recognition (in years)				4 years
Stock options, outstanding, intrinsic value (less than)		$ 16,200,000		$ 16,200,000
Stock options, outstanding, weighted average remaining contractual term (in years)				4 years
Stock options, exercisable, number (in shares)		24,160,751		24,160,751
Stock options, exercisable, intrinsic value (less than)		$ 16,200,000		$ 16,200,000
Stock options, exercisable, weighted average exercise price (in dollars per share)		$ 2.88		$ 2.88
Stock options, exercisable, weighted average remaining contractual term (in years)				4 years 8 months 4 days
Stock options				$ 300,000	300,000
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volume-weighted average stock closing price (in dollars per share)				$ 20
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volume-weighted average stock closing price (in dollars per share)				$ 30
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans		$ 384,000	559,000	$ 1,532,000	2,648,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employer maximum annual contributions per employee, percent	15.00%
Outstanding stock, percentage	1.00%
Total compensation cost recognized for stock-based compensation plans		360,000	57,000	436,000	164,000
Maximum number of shares that may be purchased (in shares)	14,163,863
Maximum number of shares that may be purchased by any one participant (in shares)	5,000
Common stock, shares, issued (in shares)	2,785,582
PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans		6,170,000	11,851,000	20,327,000	42,444,000
Unvested stock options, unrecognized stock-based compensation		18,200,000		$ 18,200,000
Cost not yet recognized, period for recognition (in years)				4 years
Eligibility for vesting period (in days)				90 days
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans		$ 21,074,000	20,603,000	$ 62,391,000	62,539,000
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock, percentage				5.00%
Common stock, shares, issued (in shares)		411,256,965		411,256,965		401,183,882
Common Class A | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)		12,851,030		12,851,030
Employee discount percentage	15.00%
Maximum common stock reserved, threshold percentage	10.00%
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)		0		0
Proceeds from stock options exercised				$ 200,000	0
2014 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, percentage of fair value of common stock				100.00%
Expiration period (in years)				10 years
2014 Plan | Stock options | Tranche one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)				4 years
2014 Plan | Stock options | Tranche two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)				5 years
2014 Plan | RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)				1 year
2014 Plan | RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)				4 years
2020 Equity and Management Incentive Plan | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock, percentage				7.00%
2020 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans		$ 27,988,000	$ 33,070,000	$ 84,700,000	$ 107,800,000

v3.24.3

Employee Benefit Plans - Schedule of Share-Based Payment Arrangement, Activity (Details)	Sep. 30, 2024 shares
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Authorized Under Plans (in shares)	54,402,264
Shares Outstanding Under Plans (in shares)	34,457,710
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Authorized Under Plans (in shares)	86,604,581
Shares Outstanding Under Plans (in shares)	39,844,072
Shares Remaining Under Plans (in shares)	19,817,658
2020 MIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Authorized Under Plans (in shares)	33,426,983
Shares Outstanding Under Plans (in shares)	23,398,889
Shares Remaining Under Plans (in shares)	0
Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Authorized Under Plans (in shares)	11,000,000
Shares Outstanding Under Plans (in shares)	6,293,605
Shares Remaining Under Plans (in shares)	0

v3.24.3

Employee Benefit Plans - Schedule of Stock-Based Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans			$ 84,686	$ 107,795
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans	$ 384	$ 559	1,532	2,648
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans	21,074	20,603	62,391	62,539
PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans	6,170	11,851	20,327	42,444
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost recognized for stock-based compensation plans	$ 360	$ 57	$ 436	$ 164

v3.24.3

Employee Benefit Plans - Schedule of Stock Option Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Number of stock options
Granted (in shares)	0	0
2020 Plan
Number of stock options
Outstanding at beginning of period (in shares)	952,900
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	(131,212)
Outstanding at end of period (in shares)	821,688
Weighted-average exercise price
Outstanding at beginning of period (in dollars per share)	$ 8.88
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	8.88
Outstanding at end of period (in dollars per share)	$ 8.88
2014 Plan
Number of stock options
Outstanding at beginning of period (in shares)	24,041,753
Granted (in shares)	0
Exercised (in shares)	(210,555)
Forfeited (in shares)	(120,650)
Outstanding at end of period (in shares)	23,710,548
Weighted-average exercise price
Outstanding at beginning of period (in dollars per share)	$ 1.45
Granted (in dollars per share)	0
Exercised (in dollars per share)	1.16
Forfeited (in dollars per share)	3.44
Outstanding at end of period (in dollars per share)	$ 2.73

v3.24.3

Employee Benefit Plans - Schedule of Total RSUs Activity (Details) - RSUs	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number of shares
Beginning balance (in shares) | shares	56,928,405
Granted (in shares) | shares	17,639,741
Released (in shares) | shares	(17,249,172)
Forfeited (in shares) | shares	(7,625,408)
Ending balance (in shares) | shares	49,693,566
Weighted-average grant date fair value per share
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 4.28
Granted (in dollars per share) | $ / shares	0.97
Released (in dollars per share) | $ / shares	4.56
Forfeited (in dollars per share) | $ / shares	1.93
Outstanding at end of period (in dollars per share) | $ / shares	$ 3.37

v3.24.3

Employee Benefit Plans - Schedule of Assumptions to Estimate Fair Value of PRSUs on Weighted Average Basis (Details) - PRSUs	12 Months Ended
	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	40.70%
Risk-free interest rate	0.50%
Dividend yield	0.00%

v3.24.3

Employee Benefit Plans - Schedule of Total PRSUs Activity (Details) - PRSUs	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number of shares
Beginning balance (in shares) | shares	32,131,532
Granted (in shares) | shares	0
Adjustment for performance condition achieved (in shares) | shares	341,459
Vested (in shares) | shares	(2,389,515)
Forfeited (in shares) | shares	(315,292)
Ending balance (in shares) | shares	29,768,184
Weighted-average grant date fair value per share
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 8.36
Granted (in dollars per share) | $ / shares	0
Adjustment for performance condition achieved (in dollars per share) | $ / shares	0.95
Vested (in dollars per share) | $ / shares	1.14
Forfeited (in dollars per share) | $ / shares	1.56
Outstanding at end of period (in dollars per share) | $ / shares	$ 8.93

v3.24.3

Employee Benefit Plans - Schedule of ESPP Valuation Assumption (Details) - ESPP - Forecast	6 Months Ended
	Nov. 21, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 months
Expected volatility	64.00%
Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average risk-free interest rate	5.40%

v3.24.3

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Effective tax rate (as percent)	0.00%	0.00%	0.00%	0.00%
Deferred tax assets, net	$ 0		$ 0
Unrecognized tax position	0		0
Penalties accrued	$ 0		$ 0		$ 0

v3.24.3

Net Income (Loss) per Share - Schedule of Continuing and Discontinued operations of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net loss from continuing operations attributable to Common Stockholders	$ (8,785)	$ (33,616)	$ (24,785)	$ (142,203)
Net (loss) income from discontinued operations attributable to Common Stockholders	$ (370)	$ (7,853)	$ 3,868	$ (686)
Denominator:
Basic weighted average number of common shares and common share equivalents outstanding (in shares)	490,180,103	480,770,283	488,501,812	480,921,520
Weighted average shares used in computing net income per share of common stock, diluted (in shares)	490,180,103	480,770,283	488,501,812	480,921,520
Basic loss per share from continuing operations (in dollars per share)	$ (0.02)	$ (0.07)	$ (0.05)	$ (0.30)
Basic earnings (loss) per share from discontinued operations (in dollars per share)	0.00	(0.02)	0.01	0.00
Diluted loss per share from continuing operations (in dollars per share)	(0.02)	(0.07)	(0.05)	(0.30)
Diluted earnings (loss) per share from discontinued operations (in dollars per share)	$ 0.00	$ (0.02)	$ 0.01	$ 0.00

v3.24.3

Net Income (Loss) per Share - Schedule of Antidilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from computation of net income (loss) per share (in shares)	103,993,986	110,908,210	103,993,986	110,908,210
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from computation of net income (loss) per share (in shares)	49,693,566	55,544,997	49,693,566	55,544,997
PRSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from computation of net income (loss) per share (in shares)	29,768,184	30,224,866	29,768,184	30,224,866
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from computation of net income (loss) per share (in shares)	24,532,236	25,138,347	24,532,236	25,138,347

v3.24.3

Commitments and Contingencies (Details)			9 Months Ended	12 Months Ended
	Oct. 23, 2024 USD ($)	Apr. 21, 2023 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 21, 2023 USD ($)	Aug. 19, 2022 action	Sep. 16, 2021 action
Loss Contingencies [Line Items]
Contingent liabilities			$ 0	$ 0
Litigation settlement, amount awarded from other party		$ 22,000,000
Insurance proceeds		$ 19,500,000
Number of derivative actions | action						2	2
Award fees and expenses					$ 2,500,000
Subsequent event
Loss Contingencies [Line Items]
Payments for legal settlements	$ 250,000

v3.24.3

Operating Segments - Additional Information (Details)	9 Months Ended
	Sep. 30, 2024 segment
Segment Reporting [Abstract]
Number of reporting segments (in segments)	1
Number of operating segments (in segments)	1

v3.24.3

Operating Segments - Schedule of Revenue by Operating Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2023
Revenue, Major Customer [Line Items]
Premiums earned, net (Net of ceded premiums)	$ 322,579	$ 301,230	$ 1,014,201	$ 932,699
Other income	8,407	4,798	19,967	15,459
Intersegment revenues	(330,986)	(306,028)	(1,034,168)	(948,158)
Net medical claims incurred	249,774	235,785	763,283	754,836
Gross profit	81,212	70,243	270,885	193,322	$ 70,243
Total assets	653,013	684,980	653,013	684,980		$ 570,671
Ceded premiums	97	106	301	341
Operating Segments | Insurance
Revenue, Major Customer [Line Items]
Premiums earned, net (Net of ceded premiums)	322,579	301,230	1,014,201	932,699
Other income	4,314	3,338	12,085	7,192
Net medical claims incurred	251,643	236,533	767,125	753,877
Gross profit	75,250	68,035	259,161	186,014
Total assets	408,381	464,942	408,381	464,942
Corporate/Other
Revenue, Major Customer [Line Items]
Premiums earned, net (Net of ceded premiums)	0	0	0	0
Other income	32,422	14,218	90,371	45,732
Net medical claims incurred	4,442	4,690	14,345	11,820
Gross profit	74,924	52,863	222,634	146,132
Total assets	918,407	905,477	918,407	905,477
Intersegment revenues
Revenue, Major Customer [Line Items]
Intersegment revenues	46,944	43,335	146,608	112,220
Intersegment revenues | Insurance
Revenue, Major Customer [Line Items]
Intersegment revenues	0	0	0	0
Eliminations
Revenue, Major Customer [Line Items]
Premiums earned, net (Net of ceded premiums)	0	0	0	0
Other income	(28,329)	(12,758)	(82,489)	(37,465)
Net medical claims incurred	(6,311)	(5,438)	(18,187)	(10,861)
Gross profit	(68,962)	(50,655)	(210,910)	(138,824)
Total assets	$ (673,775)	$ (685,439)	$ (673,775)	$ (685,439)

v3.24.3

Operating Segments - Schedule of Reconciliation of Revenue of Segments to Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022
Segment Reporting [Abstract]
Gross profit	$ 81,212	$ 70,243	$ 270,885	$ 193,322	$ 70,243
Salaries and benefits	54,995	60,567	169,717	191,985
General and administrative expenses	35,201	41,030	124,194	140,384
Premium deficiency reserve expense (benefit)	0	392	0	(6,556)
Depreciation and amortization	339	557	987	1,835
Restructuring (recoveries) costs	(538)	1,313	288	7,870
Change in fair value of warrants	0	0	17	0
Interest expense	0	0	0	7
Loss on investment	0	0	467	0
Net loss from continuing operations	$ (8,785)	$ (33,616)	$ (24,785)	$ (142,203)

v3.24.3

Restructuring Costs - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Apr. 17, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated as a percent	10.00%
Restructuring (recoveries) costs		$ (538)	$ 1,313	$ 288	$ 7,870
Depreciation and amortization
Restructuring Cost and Reserve [Line Items]
Restructuring (recoveries) costs		$ 100	$ 100	$ 100	$ 100

v3.24.3

Restructuring Costs - Schedule of Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Total restructuring (recoveries) costs	$ (538)	$ 1,313	$ 288	$ 7,870
Employee termination (recoveries) benefits
Restructuring Cost and Reserve [Line Items]
Total restructuring (recoveries) costs	(547)	58	(547)	4,620
Vendor related costs
Restructuring Cost and Reserve [Line Items]
Total restructuring (recoveries) costs	0	1,245	822	3,166
Other
Restructuring Cost and Reserve [Line Items]
Total restructuring (recoveries) costs	$ 9	$ 10	$ 13	$ 84

v3.24.3

Restructuring Costs - Schedule of Restructuring Reserve by Type of Cost (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Restructuring Reserve [Roll Forward]
Liability as of December 31, 2023	$ 5,171
(Recoveries) charges	288
Cash payments	(2,554)
Liability as of September 30, 2024	2,905
Total cumulative costs incurred as of September 30, 2024	10,109
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Liability as of December 31, 2023	1,781
(Recoveries) charges	(547)
Cash payments	(1,234)
Liability as of September 30, 2024	0
Total cumulative costs incurred as of September 30, 2024	4,248
Vendor related costs
Restructuring Reserve [Roll Forward]
Liability as of December 31, 2023	3,390
(Recoveries) charges	822
Cash payments	(1,307)
Liability as of September 30, 2024	2,905
Total cumulative costs incurred as of September 30, 2024	5,761
Other
Restructuring Reserve [Roll Forward]
Liability as of December 31, 2023	0
(Recoveries) charges	13
Cash payments	(13)
Liability as of September 30, 2024	0
Total cumulative costs incurred as of September 30, 2024	$ 100

v3.24.3

Discontinued Operations - Condensed Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 0	$ 6,456
Surety bond and deposits	0	55,089
Non-Insurance receivable	10,087	10,926
Total assets	10,087	72,471
Liabilities
Unpaid claims	1,080	2,856
Accrued salaries and benefits	0	110
Non-Insurance performance year obligation, current	4,740	15,568
Non-Insurance payable	43,121	41,565
Total liabilities	$ 48,941	$ 60,099

v3.24.3

Discontinued Operations - Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating Expenses:
Net (loss) income	$ (370)	$ (7,853)	$ 3,868	$ (686)
Discontinued operations
Revenues:
Non-Insurance revenue	(6,149)	176,038	(370)	575,311
Total revenues	(6,149)	176,038	(370)	575,311
Operating Expenses:
Net medical claims incurred	(6,009)	183,174	(5,276)	573,567
General and administrative expenses	230	717	741	2,430
Restructuring costs	0	0	297	0
Total operating expenses	(5,779)	183,891	(4,238)	575,997
(Loss) gain from operations	(370)	(7,853)	3,868	(686)
Net (loss) income	$ (370)	$ (7,853)	$ 3,868	$ (686)

v3.24.3

Discontinued Operations - Condensed Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net cash (used in) provided by operating activities	$ (8,861)	$ 34,060
Discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net cash (used in) provided by operating activities	$ (8,861)	$ 34,060

v3.24.3

Discontinued Operations - Performance Guarantee (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Non-Insurance, performance year obligation	$ 4,740		$ 4,740		$ 15,568
Amortization of the Non-Insurance performance year receivable	0	$ (182,753)	0	$ (556,211)
Amortization of the Non-Insurance performance year obligation	0	182,753	0	556,211
Discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Non-Insurance revenue	$ (6,149)	$ 176,038	$ (370)	$ 575,311

---